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ABSTRACT 
Huntington’s disease is a neurodegenerative disorder caused by expansion of the 
CAG repeat in huntingtin exon 1.  Early studies demonstrated the huntingtin gene is 
transcribed into two 3′UTR isoforms in normal human tissue. Decades later, researchers 
identified a truncated huntingtin mRNA isoform in disease but not control human brain. 
We speculated the amount of huntingtin 3′UTR isoforms might also vary between control 
and Huntington’s disease brains. 
We provide evidence that the abundance of huntingtin 3′UTR isoforms, including 
a novel mid-3′UTR isoform, differs between patient and control neural stem cells, 
fibroblasts, motor cortex, and cerebellum. Both alleles of huntingtin contribute to isoform 
changes. We show huntingtin 3′UTR isoforms are metabolized differently. The long and 
mid isoforms have shorter half-lives, shorter polyA tails, and more microRNA and RNA 
binding protein sites than the short isoform. 
3′UTR Isoform changes are not limited to huntingtin. Isoforms from 11% of 
genes change abundance in Huntington’s motor cortex. Only 17% of genes with isoform 
alterations are differentially expressed in disease tissue. However, gene ontology analysis 
suggests they share common pathways with differentially expressed genes. We 
demonstrate knockdown of the RNA binding protein CNOT6 in control fibroblasts 
results in huntingtin isoform changes similar to those in disease fibroblasts. This study 
further characterizes Huntington’s disease molecular pathology and suggests RNA 
binding protein expression may influence mRNA isoform expression in the Huntington’s 
disease brain. 
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CHAPTER I: INTRODUCTION 
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1.1 Huntington’s disease 
Huntington’s disease (HD) is an inherited invariably fatal neurodegenerative 
disorder. Individuals usually develop symptoms in their mid-thirties and death occurs 
within two decades. Early symptoms are psychiatric and cognitive changes. As the 
disease progresses motor symptoms and dementia develop. Motor symptoms start with 
aberrant eye motions, progress to involuntary movements (chorea), and end with 
bradykinesia and rigidity. In late stages, patients experience significant cognitive decline 
and have difficulty speaking, walking, and swallowing. At that point, long-term 
institutionalization is necessary. HD prevalence varies. In Asia, prevalence is low at less 
than 0.5 individuals per 100,000, whereas in Europe, the prevalence is ten times higher. 
In the United States, 2 of every 100,000 individuals are affected
1
. Currently, there is no 
treatment that alters the course of the disease. Because patients decline over decades and 
ultimately require intensive care, HD imposes a great emotional burden on families, and a 
significant cost on society. 
George Huntington first described the autosomal dominant heritability of HD in 
1872
2
. Analysis of recombination events in HD families narrowed the region down to a 
novel gene on chromosome 4
3–6
. Sequencing of the gene revealed a CAG (glutamine) 
repeat near its 5′ end7. Control DNA had a CAG repeat number of 35 or less, while HD 
patient DNA had a repeat number of 35-100. Repeat length is inversely correlated with 
age of onset and symptom severity
8,9
. The CAG number often increases between 
generations, especially when paternally transmitted
10–12
. Patients homozygous for the 
expansion have similar age of onset and phenotype; however, some studies show they 
 3 
have more rapid and severe disease symptoms
13,14
. The gene was named huntingtin 
(HTT) in honor of George Huntington. 
HTT protein is expressed ubiquitously, though its levels are highest in neurons 
and testes
15
. HTT knockout mice die prior to gastrulation
16–19
. After gastrulation, HTT is 
required for development of the central nervous system and homeostasis of cerebrospinal 
fluid
17,20–23. HTT’s role in development is independent of CAG repeat-length, and 
humans homozygous for the expansion develop normally
13,21
. One functional HTT allele 
is sufficient for normal development
24,25
. However, reduction of HTT levels below 50% 
of normal results in impaired neurogenesis
20,21
. Wild-type HTT protein interacts with 
other proteins to protect cells against toxic stimuli, mediate vesicle transport and 
endocytosis, and modulate synaptic activity; many of these functions are impaired in 
HD
26–28
. Mutant HTT protein causes neuronal disease and death by damaging autophagy, 
vesicle transport, neurotransmitter signaling, and mitochondrial function
27
. HD Pathology 
is most significant in the striatum and cortex, although by the time of death there is 
widespread brain atrophy
29,30
. 
While much is known about HTT protein, fewer studies have explored HTT 
mRNA. The HTT gene is transcribed into a sense and anti-sense transcript; the sense 
transcript makes up the vast majority of HTT
31
. Sense HTT mRNA is almost fourteen 
kilobases long, thus its structure is complex. The CAG repeat region forms a hairpin 
stabilized by the neighboring CCG repeat; the stability of the hairpin increases with CAG 
expansion
32
. HTT mRNA is normally localized diffusely around the cytoplasm, but in HD 
it forms nuclear foci
32
. Allele specific RT-qPCR of RNA from HD patient and control 
 4 
brains revealed there is more mutant than wild-type HTT in striatum and cortex from HD 
early-grade brains
33
. Thus the stability, localization, and abundance of HTT mRNA 
change in HD. 
 Wild-type and mutant HTT mRNA are spliced into multiple isoforms, although 
splice variants are of low abundance compared to the canonical splice isoform
34
. In 
human and mouse brains, HTT can be alternatively spliced to lack exon 29
35
. This 
isoform is expressed at lower levels in HD knock-in mice than in wild-type mice. Exon 
29 contains a putative binding site for an RNA nuclear export protein, suggesting the 
decrease in the exon 29-skipping isoform may cause HTT nuclear retention
35
. Another 
study identified five new HTT splice isoforms that ranged from 0.8% to 13.6% of the 
expression of the canonical transcript
36
. High throughput sequencing of human brain 
revealed 18 additional alternative splice isoforms ranging in expression from 1% to 7% to 
that of the canonical transcript
34
. It has yet to be determined if or how these splice 
isoforms contribute to HD.  
 Two alternatively polyadenylated 3′UTR isoforms make up the majority of HTT 
mRNA
37
. The putative polyA signal for the short isoform, AGUAAA, has lower in vitro 
cleavage and polyadenylation efficiency than that of the long isoform, AUUAAA
38
. The 
long isoform is 13.7 kilobases whereas the short isoform is 10.3 kilobases, and their 
relative abundance differs across tissues
37
. The long isoform is more abundant in fetal 
brain, while the short isoform is more abundant in cell lines and lymphoblasts
37
. The 
isoforms may play different roles in cells; transfected HTT exon 1-3′UTR constructs are 
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localized differently depending on the 3′UTR length, and the shorter construct forms 
more aggregates
39
.  
In HD patients and mouse models but not controls, a small amount HTT mRNA is 
misspliced and polyadenylated at a cryptic polyadenylation signal in intron 1
40
. 
Translation of this isoform will produce a toxic N-terminal protein
27
. The isoform may be 
produced via serine/argenine-rich splicing factor 6 (SRSF6), which binds to expanded 
HTT mRNA with much higher affinity than wild-type mRNA. There is a stop codon at 
the very beginning of intron 1, and immunoprecipitation of N-terminal HTT detected a 
protein of the appropriate size in HD mouse models but not controls
40
. However, it is 
unknown whether the protein represents translation of the truncated isoform, or cleavage 
of full-length HTT. Production of the truncated HTT mRNA isoform indicates HTT is 
differently polyadenylated in HD (Fig. 1.1, bottom).  
I hypothesized that the 3′UTR alternative polyadenylation of HTT and other genes 
changes in HD. There are two lines of evidence to support this hypothesis: first, as 
described, HTT itself is aberrantly polyadenylated in disease
40
; second, molecular 
processes linked to polyadenylation including DNA, RNA, and protein expression are 
aberrant in HD
41–43
. Epigenetic modifications, transcription rate, mRNA expression, and 
protein abundance affect polyA site selection
44,45
. Alterations in these processes in 
disease could impact alternative polyadenylation. I sought to characterize the 3′UTR 
isoform expression of HTT and other genes in HD. 
A study of alternative polyadenylation could provide recommendations or targets 
for HD therapy. Epigenetic and mRNA expression changes contribute to pathology in 
 6 
HD models
27,41,42
. If polyadenylation is also altered in disease, characterization of 3′UTR 
isoform abundances in HD may reveal novel therapeutic targets. In HTT, some single 
nucleotide polymorphisms (SNPs) that are frequently heterozygous in HD patients are 
exclusive to the long 3′UTR isoform46. These sites are ideal targets for interfering RNAs 
that discriminate between wild-type and mutant mRNAs; however, the short HTT 3′UTR 
isoform is more pathogenic in cells
39,46,47
. Examination of HTT mRNA 3′UTR isoform 
abundance and processing in HD patients may provide recommendations for the design 
of mutant HTT-lowering therapies. 
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1.2 Alternative polyadenylation 
1.2.1 Mechanism of alternative polyadenylation. 
Messenger RNA 3′ endonucleolytic cleavage and polyadenylation occur co-
transcriptionally (Fig. 1.1, top). During the initiation of transcription, the 3′ processing 
machinery assembles on RNA polymerase II
48
. This machinery is a multi-protein 
complex consisting of the cleavage and polyadenylation specificity factor (CPSF), 
cleavage factors I and II (CF Im, CF IIm), and the cleavage and stimulation factor (CstF)
49
. 
CF Im and CF IIm bind UGUA motifs
50
. Downstream of these motifs, CPSF recognizes a 
hexanucleotide sequence, called a polyA signal. The canonical polyA signal is 
AAUAAA; however, nucleotide variations also elicit cleavage and polyadenylation at 
lower efficiency
38,51,52
. Downstream of the polyA site, CstF recognizes U- or GU-rich 
regions and influences the cleavage location and efficiency
53. After the 3′ end processing 
machinery binds the nascent transcript, it is cleaved 10-30 nucleotides downstream of the 
polyA signal; the location of CPSF and CstF binding determines the exact cleavage site
54
. 
The rate and location of cleavage is dependent on the concentration of these 3′ processing 
factors
55
. After a transcript is cleaved, the nuclear polyA polymerase adds up to 300 
adenosines to the 3′ end of the nascent mRNA. Transcripts that have been spliced and 
polyadenylated are exported to the cytoplasm, where cytoplasmic adenylases and 
deadenylases further modulate the polyA tail length
56
.  
 8 
 
Figure 1.1. HTT mRNA is alternatively polyadenylated. (Top) During 3′ UTR (gray) cleavage 
and polyadenylation, CFIm and CFIIm bind UGUA motifs upstream of the polyA signal. CPSF 
recognizes and binds the polyA signal (AAUAAA). Downstream of the polyA signal, CstF 
recognizes U/GU-rich motifs. The relative location of CstF to the polyA signal determines the 
cleavage site. After cleavage, the transcript is polyadenylated by the polyA polymerase (PAP). 
(Bottom)  The HTT 3′ UTR has two known polyA signals, a proximal AGUAAA and distal 
AAUAAA. The 3′ UTR polyA site selected for HTT differs depending on the tissue.  Mutant HTT 
binds the SRSF6 splicing factor, leading to inappropriate retention of intron 1 (bottom). The 
misspliced transcript is cleaved and polyadenylated at the cryptic intron 1 AAUAAA polyA 
signal, resulting in a truncated mRNA that may be translated into a pathogenic protein. 
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Like HTT, most mammalian mRNAs have more than one polyA signal and site, a 
phenomenon termed alternative polyadenylation
57
. Alternative polyadenylation events 
fall into four classes. Most commonly, cleavage and polyadenylation occur at two 
different polyA signals within the same terminal 3′UTR, which does not affect the protein 
coding sequence. The other three classes involve alternative splicing and alter the coding 
sequence. Alternative splicing may generate a different terminal exon and 3′UTR. 
Missplicing can lead to cleavage and polyadenylation after a cryptic polyA signal within 
an intron, as occurs in the misspliced mutant HTT isoform. Finally, cleavage and 
polyadenylation can initiate prematurely within the coding region. These last two events 
produce a truncated transcript and protein. PolyA signal strength depends on the 
sequence of the signal and the surrounding elements. Only 58% of human polyA signals 
are the canonical signal
58. In mRNAs with more than one 3′UTR polyA signal, 
AAUAAA is usually the most distal; however, many transcripts are cleaved and 
polyadenylated at weaker, more proximal polyA signals
58–62
.  
Although proximal polyA signals are usually weaker than distal signals, they are 
transcribed first, giving them more time for recognition by CPSF. In a Drosophila 
polymerase II mutant with slower elongation rates, the polo gene shifts to shorter 
isoforms
63
. The transcription elongation factor ELL2 is loaded with CstF subunit 64 on 
RNA polymerase II; knockdown of ELL2 in plasma cells leads the immunoglobulin 
heavy-chain complex (Igh) mRNA to shift to a proximal polyA signal
64
. Pausing of RNA 
polymerase II at the promoter of genes with extended 3′UTRs in Drosophila results in 
recruitment of the RNA binding protein ELAV, which inhibits cleavage and 
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polyadenylation at proximal polyA signals
65
. Transcription activators can increase usage 
of proximal polyA signals by recruiting 3′ processing factors66. GAL4-VP16 recruits the 
RNAP II-associated factor (PAF) elongation complex to genes and stimulates cleavage 
and polyadenylation of transcripts
67
. Mediator interacts with mRNA processing factor 
heterogeneous nuclear ribonucleoprotein L (hnRNP L) to affect alternative 
polyadenylation at transcriptionally active target genes
68
. Epigenetics also impact polyA 
site usage. The mouse imprinted genes H13 and Herc3/Nap1I5 unmethylated alleles 
undergo internal polyadenylation, while the methylated alleles are polyadenylated at a 
downstream site
69,70
.  
Changes in the concentration of 3′ processing proteins can lead cells to shift to 
more proximal or distal polyA signals. Overexpression of CstF subunit 64 (CstF-64) in B 
cells causes IgM to shift to its proximal polyA site
71
. During T cell activation, increased 
levels of CstF-64 promote polyadenylation at proximal polyA sites in the nuclear factor 
of activated T-cells (NF-ATc) gene
72
. Knockdown of another 3′ processing factor, 
CFIm68, causes a widespread shift to proximal polyA signals in human embryonic 
kidney (HEK293) cells
60
. Higher expression of 3′ processing factors in proliferating cells 
than in non-dividing cells likely leads to shorter isoforms
45,73
.  
Other RNA binding proteins affect alternative polyadenylation. Polypyrimidine 
tract binding protein (PTB) and Drosophila sex lethal protein (SXL) compete with CtsF 
to bind to the pyrimdine-rich region downstream of the polyA signal, reducing efficacy of 
cleavage and polyadenylation and promoting distal polyA site usage
74,75
. Similarly, the 
RNA binding protein HuR regulates its own alternative polyadenylation by competing 
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with CstF
76
. In mouse brains, the RNA binding protein Nova hinders cleavage and 
polyadenylation at some polyA sites
77
. Epithelium-specific splicing regulatory proteins 
ESRP1 and 2 bind UG-rich elements downstream of polyA sites and prevent their use, 
potentially via inhibition of CstF binding
78
. Knockdown of another RNA binding protein, 
polyA binding protein nuclear 1 (PABPN1), caused a global shift towards proximal 
polyA signals in cells, likely because PABPN1 competes with CPSF for binding at 
proximal polyA signals
79
. U1 small nuclear ribonucleoprotein (snRNP) binds mRNAs in 
introns to prevent premature cleavage and polyadenylation at cryptic poly A sites near the 
transcript 5′ end80. Moderate decreases in U1 snRNP levels shift cleavage and 
polyadenylation to proximal 3′UTR polyA sites81. Knockdown of DICER1 causes many 
mRNAs to shift towards shorter isoforms, suggesting a role for DICER1 in isoform 
abundance beyond microRNA-mediated repression
82
. 
Tissue-specific alternative polyadenylation contributes to tissue-specific protein 
expression
83
. Many genes that are ubiquitously transcribed are expressed tissue-
specifically via alternative polyadenylation, whereas genes that are transcribed in only 
one tissue often have a single 3′UTR polyA site84. During cell transformation and 
differentiation, a subset of mRNAs alter their 3′UTR length to change their protein 
expression
84,85
. Tissue-specific 3′UTR lengths allow fine-tuning of the expression of 
mRNAs targeted by ubiquitously expressed microRNAs
62,84
. Highly proliferative tissues 
such as testes generally have shorter 3′UTR lengths, with fewer binding sites, while 
quiescent tissues such as brain have longer 3′UTR lengths62,86,87. Several factors 
contribute to tissue-specific alternative polyadenylation including the distance between 
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tandem 3′UTR polyA sites, the position of the polyA site within the 3′UTR, and tissue-
specific expression of the 3′ processing machinery or other RNA binding proteins that 
regulate alternative polyadenylation
88,89
. 
 
1.2.2 Consequences of alternative polyadenylation. 
Trans-acting proteins bind cis elements in the 3′UTR to determine mRNA 
localization and stability
90,91
. In yeast, localization of the protein Ash1 is dependent on 
interactions between the 3′UTR and the actin cytoskeleton92. Similarly, beta and alpha 
actin mRNA require the 3′UTR for appropriate cellular localization93. Alternative 
polyadenylation can change mRNA localization. Brain-derived neurotrophic factor 
(BDNF) is transcribed into two predominant 3′UTR isoforms. The longer isoform is 
localized to dendrites, where it plays a role in long term potentiation
94
. The shorter BDNF 
3′UTR stabilizes mRNA in cell bodies after depolarization95. Another neuronal mRNA, 
calcium/calmodulin dependent protein kinase II (CaMKII), is transcribed into two 
isoforms, the longer of which is localized to dendrites
96
. Isoform expression also 
mediates protein localization independently of mRNA localization. During B cell 
activation, IgM shifts to its shorter isoform, resulting in secreted IgM protein
71
. The long 
CD47 isoform acts as a scaffold to recruit RNA binding proteins to the site of CD47 
translation, where they promote translocation of the protein to the membrane rather than 
endoplasmic reticulum
97
.  
Isoforms of the same mRNA may have different stability. Destabilizing adenosine 
and uridine-rich elements, or AREs, may be exclusive to one isoform
98
. Different polyA 
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tail lengths can cause different stabilities
56,99
. The polyA tail binds polyA binding protein 
(Pab1p) during translation
100
. Longer polyA tails usually stabilize mRNAs and enhance 
their translation
101
. Transcripts with polyA tail lengths less than twenty exhibit markedly 
reduced translation
102
. MicroRNAs target and destabilize mRNAs. In T cells, mRNAs 
with extended 3′UTRs have twice as many microRNA target sites as mRNAs with short 
3′UTRs and produce less protein87. Most microRNA sites are located after the first polyA 
site
103
. RNA binding proteins bind predominately to the 3′UTR104. In yeast, deletions in 
many RNA binding proteins resulted in decreased mRNA stability
105
. The RNA binding 
protein UPF1 accumulates on long 3′UTRs, promoting nonsense-mediated decay106–108. 
Modulation of mRNA stability by RNA binding proteins leads to changes in the amount 
of protein translated
109
. 
Primary T cells transfected with reporters encoding extended 3′UTR isoforms 
produce half as much protein as cells transfected with the shorter isoform of the same 
mRNA
87
. In cancer cells, shorter isoforms of oncogenes produce ten times more protein 
than longer isoforms
110
. Neuronal activation leads the long but not short BDNF isoform 
to bind polyribosomes and increase BDNF translation, whereas the short BDNF isoform 
mediates basal BDNF translation at rest
111
. These findings may be mRNA or cell-type 
specific, as 3′UTR length does not affect the translation efficiency or stability of most 
mRNAs in mouse fibroblasts
112
. Finally, alternative splicing and polyadenylation can 
produce isoforms with different coding sequences, changing the structure and function of 
the translated protein. Polyadenylation in the coding region of the glutamyl-prolyl tRNA 
synthetase (EPRS) results in a truncated protein that increases the translation of its 
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targets, whereas the full-length protein represses translation
113
. Thus, isoform 3′UTR 
length affects protein synthesis and function. 
 
1.2.3 Alternative polyadenylation changes in disease. 
 3′UTR isoform shifts occur in several diseases. Cancer cell lines exhibit 
shortening of several mRNA 3′UTRs compared to non-transformed cells lines110. Shorter 
oncogene isoforms contribute to transformation in these cells, indicating 3′UTR 
shortening may contribute to cancer transformation independently of genetic 
mutations
110
. In patients with non-anterior uveitis, a single nucleotide polymorphism in 
the interferon regulatory factor 5 (IRF5) mRNA creates a polyadenylation site, resulting 
in a short isoform that is associated with the development of macular edema
114
. In 
Parkinson’s disease, single nucleotide polymorphisms associated with disease promote 
formation of the longest isoform of alpha synuclein. Increased levels of the alpha 
synuclein long isoform result in accumulation of the protein and localization to 
mitochondria
115
. Research on aberrant polyadenylation in disease is still ongoing, and 
altered expression of alternatively polyadenylated isoforms may be a feature of many 
more diseases. 
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1.3 3′UTR Alternative Polyadenylation in HD 
 Alternative polyadenylation and splicing happen co-transcriptionally, and changes 
in epigenetics, transcription, and mRNA expression impact polyA site selection
48,116
. 
Recent studies have found HD cells are characterized by altered epigenetics, gene 
expression, and mRNA splicing
41,42,117
. Both mutant HTT protein and mutant HTT 
mRNA contribute to these molecular changes. These findings indicate many processes 
that impact polyA site selection are deregulated in HD. 3′UTR isoforms can have 
different localization, stability, translation efficiency, and function. If aberrant alternative 
polyadenylation of HTT or other genes occurs in HD, it may impact mRNA and protein 
metabolism. 
 
1.3.1 Mutant HTT protein disrupts processes linked to alternative polyadenylation. 
The epigenome is altered in HD (Fig 1.2). 
 Epigenetic changes can alter polyA site selection
69,70
. Early studies showed 
CREB-binding protein (CBP), a histone acetyltransferase (HAT), is sequestered in HTT 
aggregates
118
. Sequestration of CBP leads to hypo-acetylation and cell toxicity
119,120
. 
Further studies revealed global HAT expression is decreased in HD cell models
121
. Hypo-
acetylation is restricted to a subset of genes that maintain neuronal identity; across 
several HD mouse and cell models, neuron-specific genes are hypo-acetylated compared 
to controls, while total acetylation levels are unchanged
122
. The promoters of the hypo-
acetylated genes lack methyl groups on histone H3 lysine 4 (H4K4me3), a marker of 
transcriptional activation
122
. In mice expressing N-terminal HTT (N171-82Q), most 
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acetylation changes are not associated with transcription changes; however, a subset of 
hypo-acetylated genes is down-regulated
123
. In striatum of another N-terminal transgenic 
mouse (R6/1), hypo-acetylated and down-regulated DNA regions include areas that drive 
transcription of nearby genes involved in maintaining neuronal identity
124
. Some 
pathways enriched among hypo-acetylated genes in N171-82Q mice are also enriched 
among differentially expressed genes in HD patient brains, suggesting hypo-acetylation 
and down-regulation of neuronal genes is a feature of HD pathology
123
.  
Many genes are differently methylated in STHdh
Q111
 cells and patient brains 
compared to controls
125,126
. Aberrant methylation alters expression of a subset of genes, 
including those involved in regulation of gene expression such as transcription factors 
and chromatin remodelers
125
. In humans, H3K4me3 profiling identified many peaks 
differently enriched between patients and controls; however, a later study of total 
methylation found few differences, potentially because the latter study corrected for cell 
heterogeneity differences between HD and control brains
125,127
. Further studies are 
needed to elucidate methylation changes in HD.  
Correction of aberrant methylation and acetylation improves phenotypes in HD 
mouse models, suggesting epigenetic changes cause pathology
41
. In transgenic R6/2 mice 
and in striatal cells derived from HTT knock-in mice (STHdh
Q111
), there is hypo-
acetylation of specific down-regulated genes; treatment with HDAC inhibitors 
normalized gene expression and reduced motor phenotypes
128,129
. HDAC inhibitors also 
exert trans-generational benefits; offspring of male N171-82Q mice treated with HDAC 
inhibitors exhibit a blunted phenotype
130
. Reducing levels of an H3K4me3 demethylase 
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in mouse primary neurons transduced with mutant HTT normalizes expression of down-
regulated genes and reduces disease phenotypes
131
. These studies suggest epigenetic 
changes contribute to HD pathology by decreasing expression of a subset of genes. 
 
Figure 1.2. Mutant HTT protein exerts epigenetic changes. (Top) In healthy cells, DNA 
(blue) is wrapped around histones (gold). Repressive methyl groups added to DNA and histones 
 18 
(Me) by methyltransferases cause DNA to be wrapped tighter, while activating methyl groups 
such as H3K4 trimethyl cause DNA to be wrapped looser. In contrast, acetylation of histones by 
histone acetyltransferases (HATs) is always activating, while removal of acetyl groups by histone 
deacetylases (HDACs) is repressive. Looser DNA is accessible to transcription factors (TFs) and 
RNA polymerase (pol2), allowing transcription. CBP acetylates histones and recruits 
transcription factors. (Bottom) In HD cells, there is decreased acetylation and H3K4 methylation, 
and increased repressive methylation of a subset of genes. CBP is sequestered in nuclear mutant 
HTT inclusions. These changes lead to decreased transcription of a subset of genes in HD. 
 
RNA expression changes in HD. 
Transcription and RNA expression impact alternative polyadenylation
116,132
. In 
HD, epigenetic alterations and aberrant transcription factor binding change mRNA and 
microRNA expression (Fig. 1.3)
41,123
. Early research found mRNA of the neuropeptides 
enkephalin and substance P is decreased in HD patient striatum
133
. R6/2 mouse brains 
also exhibited decreased mRNA for receptors of glutamine, dopamine, acetylcholine, and 
adenosine compared to controls
134
. Microarrays of striatal mRNAs from pre-phenotypic 
R6/2 and N171-82Q mice found components of signaling pathways, and inflammation 
mediators were differentially expressed
135
. Most genes with predominately striatal 
expression are down-regulated in R6/1 mice and HD patients
136
. Striatal genes 
differentially expressed in both HD patients and Yac128 mice, which harbor the full-
length mutant HTT transgene, included pro-inflammatory Cd4, interferon-induced Indo, 
and clathrin adaptor complex protein AP1S1
137
.  However, as neuronal loss is profound in 
patient striatum, these findings may be due to decreased neurons and increased glia rather 
than gene expression changes. 
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Genome-wide studies have revealed widespread mRNA expression changes in 
HD. Microarrays of mRNA from human HD and control brains found 21%, 3%, 1%, and 
0% of genes were differentially expressed in HD striatum, motor cortex, cerebellum, and 
prefrontal cortex
138
. The magnitude of expression alterations in the striatum correlated 
with disease grade. Importantly, these changes were not due to neuronal loss, as 
microarray from laser-captured neurons yielded similar results
138
. The top genes 
differentially expressed in mouse models with truncated or full-length mutant HTT are 
also differentially expressed in HD patients
139
. This result indicates the expanded 
polyglutamine repeat changes expression of a subset of mRNAs.  
Some changes in mRNA expression in HD are due to aberrant transcription factor 
binding. Wild-type HTT interacts with the transcriptional repressor REST/NRSF to 
sequester it to the cytoplasm
140
. That interaction is lost in HD, resulting in increased 
binding of REST/NRSF to DNA and repression of neuron-specific genes
140–142
. Increased 
REST activity in HD may also be due to increased REST transcription; R6/2 mice exhibit 
an Sp1-dependent increase in REST transcription compared to controls
143
. Sp1 is a 
transcription activator that recruits the transcription initiation factor TFIID to 
promoters
144
. In contrast to REST, most Sp1 targets are down-regulated in HD. Sp1 and 
TFIID both interact with full-length HTT
145,146
. This interaction is strengthened with 
polyglutamine expansion, preventing Sp1 and TFIID from binding target DNA
145
. In HD 
patient brains, many down-regulated genes have decreased binding to Sp1
147
.  
Mutant HTT interactions with the TFIID complex prevent cAMP-responsive 
element-binding protein (CREB) from promoting expression of target genes including 
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peroxisome proliferator-activated receptor gamma coactivator-1 α (PGC-1α), a 
transcriptional activator of metabolic genes
148
. Overexpression of TAF4, a subunit of 
TFIID, ameliorates transcriptional deregulation and cell death in HD cell models
149
. 
TATA binding protein (TBP), another component of TFIID, accumulates in HD patient 
brains
150
. Trinucletide expansions within the TBP gene produce a syndrome 
indistinguishable from Huntington’s disease, suggesting impaired TBP contributes to HD 
pathology
151
. Mutant HTT traps CBP, a protein that associates with CREB to activate 
transcription
118,120
. The mutant HTT N-terminus binds p53, decreasing transcription of 
p53 target genes
118,146
. In contrast, binding between N-terminal mutant HTT and nuclear 
receptor co-repressor (N-CoR) may lead to increased transcription of some genes, as N-
CoR is a transcriptional repressor
152
.  
RNA expression changes in HD extend to microRNAs (Fig. 1.3). HTT colocalizes 
in P-bodies with argonaute 2 (Ago2), and STHdh
Q111
 cells have compromised gene 
silencing
153
. Nuclear REST reduces expression of miR-124a, an inhibitor of non-neuronal 
mRNA expression
154
. Decreased transcription of miR-124a in HD contributes to loss of 
neuronal identity
155
. Other microRNA genes targeted by REST are down-regulated in 
HD
156
. Two of these, miR-9 and 9*, target REST and its cofactor, coREST; decreased 
expression of miR-9 and 9* in HD may disinhibit the REST complex in a feed-forward 
loop
155
. Another, miR-146a, targets TBP, a transcription factor implicated in HD 
pathology
150,157
. Genome-wide studies from human frontal cortex and dorsal caudate 
found 150 microRNAs are differentially expressed, many of them REST targets and 
some with target sites in genes known to be differentially expressed in HD
158
.  
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Normalizing the levels of some microRNAs reduces pathology in HD models. 
HTT-targeting microRNAs 150, 146a, and 125b are reduced in STHdh
Q111
 cells; 
transfection of these microRNAs decreases aggregates and increases cell viability
159
. 
MiR-34b is elevated in pre-symptomatic HD patient plasma; knockdown of miR-34b 
with antisense oligonucleotides alters the toxicity of mutant HTT in cells
160
. 
Overexpression of miR-22, which is down-regulated in HD patients, led to decreased 
caspase activity and improved cell viability in primary neurons exposed to mutant 
HTT
161
. In contrast, increased expression of miR-196a in HD may be neuroprotective; 
overexpression of miR-196a improves phenotypes in mouse models
162
.  
These studies measured steady-state mRNA and microRNA levels.  However, the 
correlation between altered mRNA expression and aberrant transcription factor binding 
indicates some mRNA expression differences are due to transcription changes
42
. As 
transcription is linked to alternative polyadenylation, these findings suggest alternative 
polyadenylation may change in HD. In addition, aberrant mRNA levels in HD may 
change protein abundances. The mRNA expression of 3′-end processing proteins is 
tightly linked to cell proliferative potential, suggesting mRNA expression and protein 
expression of these genes are correlated
45
. Many mRNAs are differentially expressed in 
HD; if the expression of 3′-end processing factors changes, it may cause widespread 
shifts in alternative polyadenylation. 
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Figure 1.3. Mutant HTT protein impacts RNA expression. (Top) In healthy neurons, several 
factors interact to modulate transcription. In the cytoplasm, wild-type HTT sequesters the 
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transcription repressor REST/NRSF, allowing target neuronal mRNAs and microRNAs (miRs) to 
be transcribed. Wild-type HTT associates with Ago2 in P-bodies to modulate microRNA-
mediated mRNA silencing. MicroRNA 124a silences non-neuronal mRNAs, and microRNA 9/9* 
silence REST mRNA. In the nucleus, activators such as CBP recruit transcription factors (TFs) 
such as p53 and Sp1 to DNA. Transcription factors recruit TFIID and RNA pol2, resulting in 
transcription of neuronal mRNAs and microRNAs. The CREB transcription factor promotes 
transcription of PGC-1α, which promotes transcription of metabolism mRNAs. The nuclear 
repressor N-CoR interacts with HDACs to inhibit transcription. (Bottom) In the cytoplasm of HD 
neurons, mutant HTT aggregates sequester wild-type HTT, allowing REST/NSRF to enter the 
nucleus and altering mRNA silencing via Ago2. Reduced levels of microRNAs 124a and 9/9* 
result in de-repression of REST and non-neuronal mRNAs. In the nucleus, REST/NRSF binds 
target genes and HTT inclusions sequester transcription factors p53 and Sp1, the transcription 
activator CBP, and the transcription initiation complex TFIID. This results in decreased 
transcription of genes involved in signaling and neuronal and striatal genes. Mutant HTT prevents 
CREB from activating transcription of PGC-1α, reducing transcription of metabolic genes. The 
repressor N-CoR is sequestered in HTT inclusions, and inflammatory genes are more highly 
expressed. 
 
RNA processing is aberrant in HD. 
 Alternative polyadenylation co-occurs with mRNA splicing. Deep sequencing of 
RNA from the motor cortex of HD patients revealed 593 splicing events that differed 
between patients and controls
117
. Splicing changes may be due to altered expression of 
splicing factors (Fig. 1.4). Four splicing factors—PTBP1, SFRS4, RBM4, and SREK1— 
were differentially expressed in HD. Of these, PTBP1 showed the highest correlation 
between its expression and splicing events of its target genes
117
. Other splicing changes in 
HD patient brains may be due to altered levels of serine/arginine-rich splicing factor-6 
(SRSF6)
163
. SRSF6 binds the expanded CAG repeat and may promote mis-splicing of 
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HTT into the disease-associated isoform terminating in intron 1
40
. SRSF6 modulates the 
splicing of tau protein, and increased levels of SRSF6 in HD lead to increased production 
of the tau splice isoform associated with neurodegeneration
163–165
. Altered SRSF6 levels 
also result in missplicing of the primary microtubule associated protein in dendrites, 
MAP2
166
. These studies show several processes linked to alternative polyadenylation in 
the cell— chromatin relaxation, RNA expression, and RNA splicing— are aberrant in 
HD. 
 
1.3.2 Mutant HTT mRNA disrupts processes linked to alternative polyadenylation. 
 Like mutant HTT protein, mutant HTT mRNA causes deregulation of mRNA 
splicing (Fig. 1.5)
43
. Triplet repeat RNA regions form stable hairpin structures
167
. Crystal 
structures of CAG repeat RNA reveal a helical duplex, and in vitro nuclease analysis of 
HTT mRNA found the CAG repeats form a hairpin stabilized by the neighboring CCG 
repeats
32,168
. RNA hairpins can bind and sequester proteins, causing toxicity
167
.  
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Figure 1.4. Mutant HTT protein impacts RNA processing. (Top) Splicing factors (SF) bind to 
nascent mRNA transcripts and mediate splicing and removal of introns (gray) and alternative 
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exons (colored). The splicing factor SRSF6 modulates splicing of MAP2 and Tau. Correctly 
spliced mRNAs are translated in the cytoplasm into their canonical protein isoforms (ellipses). 
(Bottom) In HD cells, splicing factors including PTBP1, SFRS4, RBM4, and SREK1 have 
decreased expression, resulting in missplicing of target mRNAs. SRSF6 accumulates in HTT 
inclusions, and increased SRSF6 levels alter MAP2 and Tau splicing. Misspliced transcripts may 
be translated into different protein isoforms (hexagons). Most HTT mRNA is spliced correctly 
(ellipses); however, SRSF6 binds to some mutant but not wild-type HTT (mHTT), producing a 
truncated HTT protein (hexagon).  
 
The atomic structure of CAG repeats and CUG repeats is similar
168
. In type 1 
myotonic dystrophy, CUG repeats in the untranslated region of DMPK mRNA form 
nuclear foci that bind and sequester the splicing protein musclebind (MBNL1), leading to 
extensive splicing changes
169–171
. Most of the pathology in myotonic dystrophy can be 
explained by sequestration of MBNL1
172
. Although the trinucleotide repeat in DMPK is 
much longer than the repeat in HTT, The similarity between the structures of CAG and 
CUG repeats prompted researchers to study whether mutant HTT mRNA sequesters 
MBNL1. Indeed, expanded HTT mRNA forms nuclear foci that colocalize with 
MBNL1
32
. Expression of long untranslated CAG-repeat RNA can induce MBNL1-
rescued splicing changes, and HD patient fibroblasts exhibit splicing changes similar to 
normal cells transfected with MBNL1 siRNAs
173
. These findings suggest HTT mRNA 
transcripts sequester MBNL1, leading to aberrant splicing. 
Interactions between expanded HTT mRNA and MBNL1 induce toxicity. 
Expression of non-translated CAG repeats in Drosophila causes neurodegeneration
174
. 
Transgenic mice that express 200 CAG repeats in the 3′UTR of EGFP exhibit muscle 
pathology due to MBNL1 sequestration, similar to that in myotonic dystrophy
175
. 
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Neuroblastoma cells transfected with an non-translated N-terminal fragment of HTT 
suffer cytotoxicity comparable to that in cells transfected with the same protein 
fragment
176
. Transfection of full-length mutant HTT into these cells results in nuclear foci 
that increase with overexpression of MBNL1
176
. Researchers deleted the start codon or 
inserted repeats in a gene 3′UTR to create these non-translated RNAs. Repeat-associated 
non-AUG (RAN) translation occurs in HD, so some toxicity may be attributable to RAN 
products
177
. However, most experiments found no detectible protein produced by the 
constructs
175,176
. These studies suggest interactions between mutant HTT mRNA and 
MBNL1 induce toxicity, as occurs in myotonic dystrophy.  
Interactions between MBNL1 and Mutant HTT mRNA may directly alter 
alternative polyadenylation. As described, MBNL is sequestered by triplet repeat 
mRNAs
32,169
. In addition to modulating alternative splicing, MBNL proteins bind the 
3′UTR of target mRNAs; depletion of Mbnl in mouse embryo fibroblasts results in 
widespread aberrant alternative polyadenylation events
178
. In myotonic dystrophy mouse 
models and patients, misregulation of alternative polyadeylation leads to a persistent 
neonatal polyadenylation profile
178
. This study indicates triplet repeat expansion mRNAs 
can cause widespread changes in alternative polyadenylation via interactions with RNA 
binding proteins
178
. HTT sequestration of MBNL1 may result in aberrant 
polyadenylation.  
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Figure 1.5. Trinucleotide-repeat RNAs impair splicing and alternative polyadenylation. 
(Top) In healthy cells, MBNL1 associates with mRNA in the ORF and 3′UTR to modulate 
splicing and alternative polyadenylation. (Bottom) In disease cells expressing trinucleotide repeat 
expansions, such HD and myotonic dystrophy neurons, repeat RNAs form hairpins that aggregate 
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into nuclear foci and sequester MBNL1. Sequestration of MBNL1 causes missplicing and 
aberrant polyadenylation of MBNL1 target transcripts. Altered splicing can result in aberrant 
protein isoforms (hexagon), and altered alternative polyadneylation can impact mRNA stability, 
localization, and translation via differences in cis elements such as destabilizing motifs and RNA 
binding protein (RBP) and microRNA target sites. 
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1.4 Conclusions 
It has been known since the early 1990s that HTT mRNA is processed into two 
3′UTR isoforms179. Since then, studies have found the 3′UTR directs mRNA localization, 
stability, translation, and function. During preparation of this dissertation, a study found 
the long HTT 3′UTR localized mutant exon 1 constructs to dendrites, whereas the short 
HTT 3′UTR constructs formed more aggregates, suggesting HTT 3′UTR length affects 
HD pathogenesis
39
. The recent finding that HTT is prematurely cleaved and 
polyadenylated in intron 1 in HD patient brains shows there are changes in HTT 
alternative polyadenylation in HD
40
. Gene expression and splicing, which occur at the 
same time as alternative polyadenylation, are deregulated in HD
48,117,138,180
. Although 
these studies show that HTT 3′UTR isoforms may differ in their pathogenicity, that HTT 
alternative polyadenylation changes in HD, and that processes linked to alternative 
polyadenylation are disrupted in HD, no study has explored the abundance or metabolism 
of 3′UTR isoforms in disease cells. 
I hypothesized that alternative polyadenylation is disrupted in HD. Here, I provide 
evidence that the abundance of HTT mRNA 3′UTR isoforms differs between HD patients 
and non-HD controls, including a novel mid-length 3′UTR isoform. I show that HTT 
mRNA 3′UTR isoforms have different localizations, half-lives, polyA tail lengths, 
microRNA sites, and RNA binding protein sites. Isoform alterations in HD are not unique 
to HTT. There are widespread changes in mRNA 3′UTR isoform expression in human 
HD motor cortex. Genes with isoform changes are associated with pathways 
dysfunctional in HD. I demonstrate that knockdown of the RNA binding protein CNOT6 
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leads to isoform amounts similar to those in HD motor cortex. My findings indicate that 
altered 3′UTR isoform expression of HTT and a subset of other genes is a feature of 
molecular pathology in HD motor cortex.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 32 
CHAPTER II: THE ABUNDANCE OF HTT MESSENGER RNA ISOFORMS 
CHANGES IN HD 
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Preface 
 The work presented in this chapter is accepted at Cell Reports as manuscript 
“Alterations in mRNA 3′UTR isoform abundance accompany gene expression changes in 
human Huntington’s disease brains” by Romo, Ashar-Patel, Pfister, and Aronin. 
 This work was a collaborative effort. Caleigh Smith and Stevie Yang assisted 
with optimizing the allele-specific qPCR. Faith Conroy, and Rachael Miller performed 
mouse genotyping. Ami Ashar-Patel developed the PAS-seq protocol. Yasin Kaymaz 
provided advice on PAS-seq data analysis. Alicia Bicknell provided the ethinyl-uridine 
pulse chase protocol. Brian Quattrochi provided the universal primer sequence for 
isoform-specific qPCR. Julia Alterman provided the siRNA to the HTT open reading 
frame. The DiFiglia lab (Massachusetts General Hospital) provided HD and control 
neural stem cells. 
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2.1 Summary 
There are three known isoforms of HTT mRNA. A truncated (7.9 kb) isoform is 
generated via termination at a cryptic polyadenylation (polyA) signal in the first intron
40
. 
This isoform is of low abundance. Its presence in HD patients and mouse models, but not 
controls, suggests it may be associated with disease
40
. The two predominant HTT mRNA 
isoforms are generated by alternative polyadenylation in the 3′UTR37. The short (10.3kb) 
3′UTR isoform predominates in dividing cells such as lymphoblasts37. The long (13.7kb) 
isoform predominates in nondividing cells such as neurons
37
. It has not been established 
whether the abundance or metabolism of HTT mRNA 3′UTR isoforms changes in HD. 
Although many genes exhibit expression and splicing differences in HD, 3′UTR isoform 
expression changes have not been investigated
34,138,180
. 
Quantitative PCR of the HTT long isoform revealed the abundance of HTT 
mRNA 3′UTR isoforms differs between human HD and control motor cortex, 
cerebellum, fibroblasts, and neural stem cells. Isoform shifts are tissue-specific, occur in 
at least two peripheral tissues, and arise from both the mutant and the wild-type allele. 
PolyA site sequencing identified a novel mid-length HTT 3′UTR isoform that is 
conserved in mice and also changes abundance in HD. I found the short, mid, and long 
HTT isoforms have different localizations, half-lives, polyA tail lengths, RNA binding 
protein sites, and microRNA sites. These results further our understanding of HTT 
mRNA metabolism and provide recommendations for the design of allele-specific HD 
therapies. 
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2.2 Results 
2.2.1 The abundance of HTT mRNA 3′UTR isoforms changes in Huntington’s 
disease.  
I identified two abundant HTT mRNA 3′UTR isoforms in public 3′ sequencing 
data (Fig. 2.1A)
84
. As in previous studies, I found HTT mRNA isoform abundance varies 
across normal tissues: the longer isoform predominates in the brain, neuronal precursor 
(NTERA2) cells, breast, and ovary, whereas the shorter isoform predominates in testes, 
B-cells, muscle, and human embryonic kidney (HEK293) cells (Fig. 2.1B)
37
.  
To determine whether HTT mRNA isoform abundance changes in HD, I 
performed RT-qPCR of the HTT long isoform on patient cerebellum, motor cortex, 
fibroblasts, and neural stem cells normalized to total HTT expression. HD cerebellum 
samples were from grade 2, 3, or 4 brains, whereas motor cortex samples were from 
grade 1 and 2 brains (Table 2.1). HD brain grades are based on the degree of striatal 
degeneration and gliosis. Grades range from 1 (50% neuronal loss) to 4 (95% of neuronal 
loss)
181
. There is limited involvement of the cerebellum in all grades, although cerebellar 
atrophy and sporadic Purkinje cell loss is seen in grades 3-4
30,181,182
. Cortical neuronal 
loss and gliosis are variable between samples
181,183
. Typically, 10% of cortical neurons 
are lost in grade 1 with minimal gliosis, and up to 40% are lost in grade 2 with evident 
gliosis 
181,183
. Neuronal loss can confound gene expression studies. I chose to analyze 
HTT isoform expression in cortex and cerebellum rather than in the more- affected 
striatum because neuronal loss is more limited in these regions. 
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Figure 2.1. HTT 3′UTR isoforms have tissue-specific abundance.  
(A) NTERA2 cell 3′seq reads mapping to the HTT 3′UTR. (B) Quantification of HTT 3′UTR 
isoform 3′seq reads relative to total HTT 3′UTR isoform reads across several human tissues and 
cell lines. 
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Table 2.1. Human samples used for qPCR and PAS-Seq.  
 Sample origin region age sex CAG # diagnosis RIN 
PMD 
(hr:min) 
  T164 NY CB 41 M 
  
6.8 7:01 
  T2010 NY CB 92 F 
  
6 14:40 
  T190 NY CB 92 F 
  
4.7 4:00 
  H109 NZ MCx 81 M 15/18 
 
7 7 
  H122 NZ MCx 72 F 15/17 
 
7.2 9 
  H123 NZ MCx 78 M 17/20 
 
7 7.5 
  H137 NZ MCx 77 F 18/20 
 
7 12 
  H148 NZ MCx 64 M 17/18 
 
6.3 7 
  H150 NZ MCx 78 M 16/22 
 
5.6 12 
  T343 NY MCx 62 M 
  
6.2 8:16 
  T144 NY MCx, CB 88 F 
 
ALS 6.2, 5.3 
 
  T139 NY MCx, CB 57 M 
  
6.1, 6 
 
  T551 NY MCx, CB 77 F 
  
6.4, 7.2 13:34 
  T1488 NY MCx, CB 88 F 
 
AD 6.3, 6.3 12:30 
  T145 NY MCx, CB 57 F 
  
5, 5.2 9:14 
  T1327 NY MCx, CB 72 F 
 
AD 4.4, 6.3 25:55 
  T128  NY CB 50 M 
 
HD 4/4 7.8 41:25 
  T310 NY CB 49 F ?/42 HD 4/4 7.4 8:30 
  T550 NY CB 82 F 
 
HD 2/4 3 19:29 
  T269 NY CB 61 F ?/47 HD 4/4 6.1 23:00 
  T150 NY CB 60 M ?/46 HD 4/4 7.2 12:45 
  T1991 NY CB 53 M ?/46 HD 3/4 8 11:17 
  HC086 NZ MCx 46 M 
 
HD 1/4 2.4 18 
  HC132 NZ MCx 32 M 
 
HD 1/4 5.2 14 
  HC074 NZ MCx 42 F 17/42 HD 1/4 3.1 11 
  HC051 NZ MCx 58 M 16/43 HD 1/4 5.6 4.5 
  HC081 NZ MCx 70 F 19/41  HD 1/4 7 8 
  HC083 NZ MCx 80 M 20/40  HD 1/4 2.7 9 
  HC092 NZ MCx 72 M 17/41 HD 1/4 6.9 5 
  HC103 NZ MCx 41 M 19/39 HD 1/4 3.6 11 
  HC105 NZ MCx 67 F 15/42 HD 1/4 7.5 9 
  HC132 NZ MCx 32 M 17/47 HD 1/4 2.5 14 
  HC137 NZ MCx 83 M 17/42 HD 1/4 4 13 
  HC061 NZ MCx 65 M 18/46  HD 2/4 6.4 6 
  HC062 NZ MCx 78 F 18/43  HD 2/4 5.7 6 
  HC069 NZ MCx 50 F 16/46 HD 2/4 2.9 20 
  HC076 NZ MCx 71 M 19/42 HD 2/4 3.2 16 
  HC080 NZ MCx 45 F 24/43  HD 2/4 6.5 15 
  HC088 NZ MCx 57 F 17/44 HD 2/4 2.6 19 
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  HC111 NZ MCx 91 F 15/40 HD 2/4 2.4 18 
  HC113 NZ MCx 58 M 28/44 HD 2/4 6.4 14 
  HC114 NZ MCx 53 F 21/47 HD 2/4 6.6 12 
  HC115 NZ MCx 56 M 16/46 HD 2/4 4 16 
  HC120 NZ MCx 51 M 10/46 HD 2/4 7 15 
  HC133 NZ MCx 65 M 17/43 HD 2/4 4.9 14 
  T273 NY MCx, CB 67 M ?/43 HD 2/4 6.4, 6.1 32:35 
  T289 NY MCx, CB 54 F 
 
HD 2/4 6.1, 6.2 24:30 
  T309 NY MCx, CB 80 F ?/41 HD 2/4 4.9, 6.5 9:25 
  T461 NY MCx, CB 77 M ?/42 HD 2/4 5, 6.1  19:28 
  T3049 NY MCx, CB 72 M 
 
HD 2/4 6, 6 40:50 
  T1482 NY MCx, CB 76 F 
 
HD 2/4 6.3, 6 61:55 
  
         
  
average 
age 
M/F 
       
 
73.50 7/9 
       
  60.72 20/16 
       
           
 
Samples were obtained from the New York (NY) and the Neurological Foundation of 
New Zealand (NZ) brain banks. Samples highlighted in red are HD while those with blue 
are controls. Purple text corresponds to cerebellum while green text corresponds to motor 
cortex. Samples in bold italics were also used for PAS-Seq. HD=Huntington’s disease, 
ALS=amyotrophic lateral sclerosis, AD=Alzheimer’s disease, M=male, F=female. 
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I found a significant (p=0.01) 1.6-fold increase in the long 3′UTR isoform relative 
to total HTT mRNA in patient cerebellum. Conversely, there is a significant (p=0.00003) 
2.5-fold decrease in the long isoform in patient motor cortex (Fig. 2.2A). Patient 
fibroblasts and neural stem cells also exhibit a significant decrease in the long isoform 
(Fig. 2.2B, 2-fold, p=0.0003; and 3.3-fold, p=0.00004 respectively). These results 
demonstrate the abundance of HTT mRNA 3′UTR isoforms changes in HD in a tissue 
and cell-specific manner.  
  
2.2.2 HTT mRNA isoform changes extend to liver and muscle and arise from both 
alleles.  
I used HD model mice to determine if disease-associated isoform changes extend 
beyond brain. I bred mice that lack murine Htt, but harbor full length human HTT with 
either 18 or 128 CAG repeats on a yeast artificial chromosome (Yac18, Yac128)
16,184
. 
Like patients, Yac128 cerebellum exhibits an increase (1.7-fold, p=0.05) in the long HTT 
mRNA isoform compared to yac18 mouse cerebellum. Isoform differences extend to 
muscle (quadriceps) and liver, with a 2.2-fold increase (p=0.007) and a 1.6-fold decrease 
(p=0.03) in the HTT long mRNA isoform respectively (Fig. 2.3). These findings indicate 
that at least two non-brain tissues exhibit tissue-specific HTT mRNA isoform changes. 
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Figure 2.2. HTT 3′UTR isoforms change their relative amounts in HD. 
(A) qPCR of the HTT mRNA long 3′UTR isoform (long) normalized to total HTT expression 
(total) in HD patient and control cerebellum (CB) and motor cortex (MCx). *, **, and *** signify 
p<0.05, 0.005, and 0.0005. (B) qPCR as in C, using patient or control fibroblasts or neural stem 
cells (NSCs) differentiated from fibroblasts. 
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Figure 2.3. HTT 3′UTR isoform changes extend to muscle and liver in an HD transgenic 
mouse model. 
Quantitative PCR of the HTT long 3′UTR isoform (long) normalized to total HTT expression 
(total) across Yac128 and Yac18 mouse tissues. CB=cerebellum. *, **, and *** signify p<0.05, 
0.005, and 0.0005. 
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Figure 2.4. Both HTT alleles change their 3′UTR isoform amounts in HD. 
(A) Allele-specific qPCR using SNP rs362267C/T in the HTT long 3′UTR isoform (long) 
normalized to total HTT expression (total) in patient and control cerebellum. (B) Allele-specific 
qPCR in patient and control motor cortex, as in A. (C) Correlation of HTT allele abundance 
within each HD or control (con) cerebellum (CB) or motor cortex (MCx) sample; r=0.83. 
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Altered HTT mRNA isoform abundance in HD patient brains could arise from the 
wild-type allele, the mutant allele, or both. To determine which allele is responsible for 
the changes, I performed allele-specific qPCR on human cerebellum and motor cortex 
samples heterozygous for single nucleotide polymorphism (SNP) rs362267 in the HTT 
long, but not short, 3′UTR. This SNP heterozygosity is not linked to the CAG repeat; in 
some patients, the C allele is expanded, whereas in others the T allele is expanded. The 
long isoform qPCR probe matched either the C or the T SNP. These probes efficiently 
and specifically amplify the matching but not the nonmatching allele. The amounts of 
both mutant and wild-type long HTT isoform are changed in HD cerebellum (p=0.01, 
0.04) and motor cortex (p=0.01, 0.06) compared to controls (Fig. 2.4A,B). The direction 
of isoform changes is consistent between alleles in each patient (Fig. 2.4C, correlation 
coefficient 0.83). Thus the disease-associated change in HTT mRNA isoforms arises from 
both alleles. 
 
2.2.3 PolyA site sequencing identified a novel conserved mid-3′UTR isoform of HTT 
mRNA whose abundance changes in disease.  
To identify unknown 3′UTR isoforms of HTT, I used a new polyA site 
sequencing method, PAS-seq (Fig. 2.5). PAS-seq requires minimal RNA input to 
produce high quality sequences, or reads. A high percentage (~95%) of these reads map 
to the genome (Fig. 2.6). I observe good inter-sample correlation using this method 
(average Pearson’s r=0.88). The PAS-seq reverse transcription primer can anneal to 
mRNA polyA tails and polyA sequences encoded in the genome. I excluded 
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genomically-primed reads from my analysis (Fig. 2.5B, see methods)
185
.  
Using PAS-seq, I identified a novel 12.5kb isoform of HTT expressed in both 
control and disease human cerebellum and motor cortex with abundance similar to the 
short 3′UTR isoform (Fig. 2.7A). The mid isoform has the features of a true polyA site 
and is not due to internal polyA priming (see methods, CleanUpdTSeq). I performed 
PAS-seq on mice to test if the mid 3′UTR isoform is conserved. I used wild-type and 
Q140 HD mice, which harbor 140 CAG repeats knocked into the mouse HTT genomic 
locus
186
. The mid-3′UTR isoform, and the short and long 3′UTR isoforms, are present in 
wild-type and Q140 mice (Fig. 2.7A). A polyA signal is required for mRNA cleavage 
and polyadenylation. There is a putative polyA signal (AAUGAA) located twenty 
nucleotides upstream of the mid-3′UTR isoform polyA site that has lower in vitro polyA 
efficiency than the short and long isoform signals
38,187
. This polyA signal and site as well 
as the surrounding regions are conserved between mice and humans (Fig. 2.7B,C). I re-
analyzed public 3′ sequencing data to quantify the mid isoform188. Like the short and long 
isoforms, the mid isoform exhibits tissue-specific expression, although it is less than 3% 
of total HTT in all tissues (Fig. 2.7D).  
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Figure 2.5. PAS-seq assays global isoform abundance. (A) Schematic of PAS-seq library 
preparation. (B) Schematic of the PAS-seq data analysis pipeline on Tbr1, an exemplary gene 
with two 3′UTR isoforms.  
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Figure 2.6. PAS-Seq produces high quality reads. (A) Representative library pre-processing 
workflow showing retention of the majority of reads through quality-control steps. (B) 
Representative library sequence length distribution (top) and per base phred score (bottom) after 
pre-processing, generated by the Fastqc package. 
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Figure 2.7. PAS-seq revealed a novel HTT mid-3′UTR isoform with tissue-specific 
abundance. (A) PAS-seq peak coordinates mapping to the HTT 3′UTR from HD patient and 
control cerebellum (CB) and motor cortex (MCx), and Q140 and wild-type (WT) mouse striatum 
(Str). (B) Needleman-Wunsch alignment of the human (top) and murine (bottom) HTT 3′UTR 
around the short, mid, and long 3′UTR isoform polyA signals (blue) and sites (yellow). (C) NCBI 
 48 
BLAST alignment score of the human and mouse HTT 3′UTR; arrows indicate the three polyA 
sites at 600, 2763, and 3903 bases into the human 3′UTR. (D) HTT mid 3′UTR isoform 3′seq 
reads relative to total HTT 3′UTR reads across several human tissues and cell lines. 
 
The abundance of the mid-3′UTR isoform also changes in HD. I compared PAS-
seq read counts (normalized to sequencing depth) for each HTT isoform. In HD motor 
cortex, the abundance of the short isoform is unchanged while the abundance of the mid-
isoform is increased by 2.8-fold (p=0.005) and the abundance of the long isoform is 
decreased 1.4-fold (p=0.01). In cerebellum, the abundance of the short isoform decreases 
by 1.8-fold (p=0.02), and the abundance of the mid and long isoform remains unchanged, 
indicating the increase in the long isoform relative to total HTT detected by qPCR is 
mostly due to a decrease in the short isoform (Fig.  2.2A). To verify HTT isoform shifts 
are not solely due to changes in gene expression, I calculated the fraction of total HTT 
each isoform contributes.  Indeed, isoform changes were still significant after 
normalizing to gene expression (Fig. 2.8A,B bottom tables).  In addition, isoform 
changes can’t be explained by gene expression alterations: total HTT expression is 
decreased by 1.4-fold in HD motor cortex but unchanged in cerebellum compared to 
controls (Fig. 2.8C). 
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Figure 2.8. The abundance of the HTT mid-3′UTR isoform also changes in HD. (A) Read 
counts of each isoform normalized to depth (graph, top table) as well as contribution of each 
3′UTR HTT isoform to total HTT expression (bottom table) in control and HD motor cortex. (B) 
Read counts as in A, in control and HD cerebellum. (C) Total HTT expression in HD versus 
control motor cortex (MCx) and cerebellum (CB). * signifies p<0.05. 
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2.2.4 HTT mRNA 3′UTR isoforms have different localizations and half-lives.  
3′UTR length affects mRNA stability, translation, and localization132. To 
determine how shifts in HTT isoform abundance affect HTT mRNA metabolism, I 
assessed the localization and stability of HTT isoforms in SH-SY5Y (human 
neuroblastoma) cells. These cells have neuronal characteristics and express short, mid, 
and long HTT 3′UTR isoforms, making them a model of HTT mRNA metabolism in 
human brain
189
. To assay the localization of HTT isoforms, I extracted RNA from nuclear 
and cytoplasmic compartments and performed isoform specific qRT-PCR on RNA from 
each (Fig. 2.9). I found about three times as much of all HTT isoforms are localized in the 
cytoplasm than in the nucleus in SH-SY5Y (Fig. 2.10A). To determine if isoform 
localization changes in disease, I assayed RNA from HD and wild-type fibroblasts. All 
HTT isoforms had a lower cytoplasmic to nuclear expression ratio in fibroblasts than in 
SH-SY5Y cells. As in SH-SY5Y cells, I found little difference between the localization 
of the HTT long and short isoforms; however, the mid isoform was significantly more 
abundant in the cytoplasm than the other isoforms in wild-type (p<0.0001) and disease 
(p=0.02) fibroblasts. The ratio of cytoplasmic to nuclear transcripts is significantly lower 
in HD fibroblasts than in wild-type fibroblasts for all three isoforms (short p=0.01, mid 
p=0.0003, long p=0.009), suggesting more HTT mRNA localizes to the nucleus in HD, as 
has been reported
32
.  
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Figure 2.9. Isoform specific qPCR separately measures all HTT isoforms. (A) Total RNA is 
reverse transcribed (RT) with an oligo d (T) primer with a 3′ universal adaptor sequence (blue). 
cDNA is amplified during qPCR with an HTT-specific forward primer and the universal reverse 
primer. (B) The short and mid isoform forward primers will also anneal to the long isoform; 
however, the long isoform cannot be amplified during the short extension time, yielding only the 
short or mid isoform PCR product when reactions are run on a gel. 
 
To study the stability of HTT isoforms, I incubated SH-SY5Y cells with labeled 
uridine, and collected labeled RNA 0, 3, 6, 9, and 12 hours after washing away the 
modified nucleotide (see methods). I performed isoform specific qRT-PCR on the RNA 
to determine the relative stability of the HTT isoforms. I found the HTT short, mid, and 
long mRNA isoforms have significantly different half-lives; the short isoform half-life is 
longer than the long isoform half-life, and the mid isoform is the shortest lived  (Fig. 
2.10B). This finding suggests that the altered relative abundance of HTT isoforms in HD 
brains is accompanied by a change in total HTT half-life.  
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Figure 2.10. HTT 3′UTR isoforms have different localization and half-lives. 
(A) Cytoplasmic versus nuclear abundance of HTT 3′UTR isoforms across cell lines. Data points 
are the average of triplicates with standard deviation. *, **, and *** signify p<0.05, 0.005, and 
0.0005. (B) Abundance of labeled HTT 3′UTR isoforms in SH-SY5Y cells at various time points 
after a 12-hour eithinyl-uridine pulse measured by isoform-specific qPCR. Data points are the 
average of triplicates with standard deviation. 
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2.2.5 HTT mRNA 3′UTR isoforms have different polyA tail lengths, RNA binding 
protein sites, and microRNA sites.  
The different stability of the HTT 3′UTR isoforms could be due to different polyA 
tail lengths, microRNA sites, or RNA binding protein sites
56,132
. To determine the polyA 
tail length of the HTT 3′UTR isoforms, I added a universal sequence to the 3′ end of the 
mRNA polyA tail that was used as a priming site during isoform-specific PCR. PCR 
products were resolved on a gel, enabling quantification of poly-A tail length (Fig. 
2.11A). I found the HTT short isoform has a poly-A tail length of about sixty in both SH-
SY5Y cells and in patient and control fibroblasts, whereas the HTT long and mid 
isoforms have very short polyA tail lengths of about ten and four (Fig. 2.11B,C). Recent 
studies found polyA tail length is correlated with stability, and the rate of mRNA 
translation drops rapidly as the polyA tail length decreases below twenty 
nucleotides
102,190
. The short polyA tail length of the mid and long HTT isoforms 
compared to the short isoform may explain their lower half-lives. 
To identify microRNA sites that differ between isoforms, I used the 
bioinformatics tool TargetScan. This program predicts microRNA target sites based on 
several local factors known to affect microRNA binding strength and specificity
191
. I 
screened predicted microRNA binding sites for microRNAs expressed in human brain. I 
found several sites exclusive to the mid and long HTT 3′UTR (Fig. 2.12A). These sites 
may contribute to differences in stability between these isoforms and the short HTT 
isoform
192
. To test this hypothesis, I transfected SH-SY5Y cells with mimics of 
microRNAs 221, 137, or both (Fig. 2.12B).  MicroRNA 137 exclusively binds the long 
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isoform, while microRNA 221 has an 8-mer binding site in the long isoform and a 6-mer 
binding site in the mid and long isoforms. I found the microRNA 137 mimic had no 
effect on isoform abundances, but transfection of the microRNA 221 or microRNA 221 
and 137 mimics reduced the abundance of the long and mid but not short isoform relative 
to total HTT (2.12C) or to GAPDH (Fig. 2.12D). These results show at least one 
microRNA exclusively degrades the long and mid HTT transcripts, likely contributing to 
the lower stability of these isoforms compared to the short isoform. 
To identify RNA binding protein sites that differ between isoforms, I used the 
CLIPdb and starBase CLIP-Seq databases
193,194
. I found several brain-expressed RNA 
binding protein sites exclusive to the long or mid and long HTT isoforms that may affect 
their stability (Fig. 2.12B). MicroRNAs and RNA binding proteins likely interact with 
HTT binding sites in motor cortex and cerebellum; however, brain cell and region-
specific expression of these factors is not established. Based on these results, I expect the 
relative decrease of the HTT long isoform in HD motor cortex is accompanied by an 
increase in HTT translation due to increased polyA tail length and increased stability.  
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Figure 2.11. HTT 3′UTR isoforms have different polyA tail lengths.  
(A) A universal sequence is added to the 3′ end of the polyA tail during reverse transcription. 
HTT isoform-specific PCR is then performed with the universal sequence as a reverse priming 
site and an isoform-specific region as the forward priming site. The polyA tail length is the PCR 
product length after subtraction of the universal primer length (28 nucleotides, NT) and the 
distance from the forward primer to the polyA site (87 NT for the long isoform, 79 NT for the 
mid isoform, 85 NT for the short). (B) Agarose gel of HTT 3′UTR isoform PCR products from 
the polyA tail length assay; S=short, M=mid, L=long. (C) Polyacrylamide gel of HTT short and 
long 3′UTR isoform PCR products from the polyA tail length assay. 
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Figure 2.12. HTT 3′UTR isoforms have different RNA binding protein sites and microRNA 
target sites. (A) Brain-expressed microRNA target sites in the HTT 3′UTR predicted by 
TargetScan. (B) Brain-expressed RNA binding protein sites in the HTT 3′UTR identified in 
public CLIP-Seq datasets. (C) Quantitative PCR of HTT 3′UTR isoforms normalized to total HTT 
expression in SH-SY5Y cells after transfection of microRNA mimics with targets exclusive to the 
HTT long or mid and long 3′UTR isoforms. *, **, and *** signify p<0.05, 0.005, and 0.0005. (D) 
Quantitative PCR of HTT 3′UTR isoforms normalized to GAPDH expression in SH-SY5Y cells 
after transfection of microRNA mimics with targets exclusive to the HTT long and mid 3′UTR 
isoforms. NT (non-targeting) miR is a C. Elegans microRNA mimic. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 58 
 
2.3 Discussion 
 
I sought to characterize the metabolism of HTT 3′UTR isoforms and to determine 
whether altered HTT 3′UTR isoform abundance is a feature of HD. I found the abundance 
of HTT 3′UTR isoforms is altered in HD motor cortex, cerebellum, fibroblasts, and neural 
stem cells. Abundance changes extend to peripheral tissues in Yac128 model mice and 
arise from the mutant and wild-type allele. PAS-seq identified a novel mid 3′UTR 
isoform of HTT that also changes in disease. I found HTT 3′UTR isoforms have different 
localization, half-lives, polyA tail lengths, microRNA sites, and RNA binding protein 
sites. Thus, isoform abundance changes in HD likely impact total HTT metabolism.  
HTT mRNAs form nuclear foci in HD cells that sequester splicing proteins
32
. I 
found the predominant HTT isoforms have similar localization, and the nuclear 
abundance of all HTT isoforms increases in HD; thus, the increase in nuclear HTT in HD 
is likely not due to isoform shifts. While the distribution of the HTT long and short 
3′UTR isoforms is similar, the mid isoform is significantly more cytoplasmic. The 
increase in the mid isoform in HD brain may be accompanied by an increase in 
cytoplasmic HTT accessible to the ribosome. However, this isoform is of low abundance 
and is unlikely to have a great effect on HTT protein expression.  My study only assayed 
nuclear versus cytoplasmic isoform localization. The 3′UTR is known to direct mRNAs 
to dendrites
96,111
. A recent study of HTT isoforms found the long but not short 3′UTR 
localizes HTT mRNA to dendrites in cultured neurons
39
. Further studies are necessary to 
determine if the dendritic localization of HTT isoforms changes in HD. 
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 Isoform changes may contribute to region-specific pathology in HD. The short-
isoform has a longer half-life and polyA tail than the other isoforms. Thus, the shift to the 
short isoform in HD motor cortex is expected to result in an increase in total HTT half-
life and translation
101
.  This is in contrast to findings from a recent study that found there 
is no difference in HTT mRNA abundance between cells transfected with a HTT short 
isoform construct and those transfected with a long isoform construct
39
. However, 
researchers measured steady-state mRNA levels of an overexpressed construct rather than 
stability of endogenous HTT transcribed from its native gene context. The study also 
found the short isoform construct produced more HTT protein and aggregates in cells, 
suggesting the mutant short isoform is more pathogenic than the long isoform
39
. Thus, the 
shift to the short HTT isoform in HD motor cortex likely contributes to HD pathogenesis, 
while the shift to the long isoform in the cerebellum may be protective. The study did not 
examine the role of the mid isoform, which also increases in HD. Further research is 
necessary to determine the impact of HTT isoform changes on HD pathogenesis, and 
whether isoform changes are casual or consequential. 
My study of HTT isoform abundance provides specific recommendations for 
allele-specific HTT-lowering therapies.  Many frequently-heterozygous SNPs are located 
in the HTT 3′UTR46.  I found the abundance of the long isoform decreases 2.5-fold in HD 
motor cortex compared to controls.  Thus SNPs exclusive the long HTT isoform are not 
ideal therapeutic targets.  However, further characterization of the role of HTT isoforms 
in HD is necessary. If the short isoform is more associated with pathology in HD patients, 
it will be the ideal target for RNA interference in HD.  
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2.4 Materials and methods 
2.4.1 Samples. The New York Brain Bank and The Neurological Foundation of New 
Zealand Brain Bank supplied fresh frozen human brain samples. Three HD and three 
control fibroblast lines were obtained from the Coriell Cell Repository. The M. DiFiglia 
lab kindly supplied neural stem cell pellets (Massachusetts General Hospital). SH-SY5Y 
cells were obtained from ATCC. The Cure Huntington’s Disease Initiative (CHDI) 
supplied Q140 mice. Mice heterozygous for null murine Htt were supplied by X. W. 
Yang (University of California Los Angeles) and bred with Yac18 mice supplied by M. 
Hayden (University of British Columbia) and Yac128 mice (Jackson Labs). Wild-type 
mice were obtained from Jackson Labs. For Q140, wild-type, Yac18 null-null, and 
Yac128 null-null mouse experiments, 7-9 month mice were sacrificed, and brain regions 
were dissected and stored in RNA-later prior to RNA extraction.  
 
2.4.2 Mouse genotyping. Mouse ear punches were digested in 50mM sodium hydroxide 
at 95°C for twenty minutes. Tris-HCl (pH 8.0) was added to a final concentration of 
0.1M. To determine genotype, DNA in 1μl of the supernatant was amplified and resolved 
as follows. For Yac18 and Yac128 mice, PCR was performed with PrimeStar GXL 
polymerase (Clontech) and 0.5μM forward and reverse primers 5′-GCCTCCGGGGACT 
GCCGTGC-3′ and 5′-CGGCTGAGGCAGCAGCGGCT-3′. The reaction was incubated 
at 98°C for 1 minute; 30 cycles of 98°C for 10 seconds and 68°C for 30 seconds; and 
68°C for 10 minutes. For null murine Htt mice, PCR was performed with FlashTaq 
Master Mix (Empirical Bioscience) and 0.4μM primers as follows: for murine Htt, 5′-
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ACGCATCCGCCTGTCAATTCTG-3′ and 5′-CTGAAACGACTTGAGCGACTC-3′; 
and for the null cassette, 5′-AACACCGAGCCGACCCTGCAG-3′ and 5′-
CCACCATGATATTCGGCAAGCAG-3′. The reaction was incubated at 94°C for 16.5 
minutes; 35 cycles of 94°C for 20 seconds, 65 °C for 30 seconds, and 72°C for 30 
seconds; and 72°C for 5 minutes. For Q140 mice, PCR was performed with FlashTaq 
Master Mix (Empirical Bioscience) and 0.4μM forward and reverse primers 5′- 
CTGCACCGACCGTGAGTCC-3′ and 5′-GAAGGCAC TGGAGTCGTGAC-3′. The 
reaction was incubated at 95°C for 5 minutes; 40 cycles of 94°C for 20 seconds, 67°C for 
30 seconds, and 72°C for 15 seconds; and 72°C for 5 minutes. All PCR products were 
resolved on a 1.5% agarose, 1x TAE gel and compared to expected product size for each 
genotype. 
 
2.4.3 Quantitative RT-PCR. Total RNA was extracted using Trizol (Ambion), and RNA 
quality was assessed by Bioanalyzer (Agilent). RNA was treated with TurboDNAse 
(Ambion), and cDNA was synthesized from 2μg total RNA using SuperScript IV 
(Invitrogen) with oligo d(T)20 priming per manufacturer’s instructions. Quantitative PCR 
was performed with 1.8μl cDNA, 1μM forward and reverse primers, and QuantiFast 
SYBR green master mix (Qiagen). The reaction was incubated at 95°C for 5 minutes, 
followed by 40 cycles of 95°C for 10 seconds and 60°C for 30 seconds. The isoform:total 
mRNA or total mRNA:GAPDH mRNA was calculated using the ΔΔCt method. All 
primers were validated by relative standard curve, and primer pairs amplified targets with 
85-115% efficiency in the linear range. I verified primer specificity by running qPCR 
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products on a 2% agarose, 1x TAE gel, extracting the bands using the QIAquick Gel 
Extraction Kit (Qiagen), and Sangar sequencing the bands with the forward and reverse 
PCR primers. I compared HD and control sample averages with unpaired two-tailed t-
tests using GraphPad Prism version 6.00 for Windows, GraphPad Software, La Jolle 
California USA, www.graphpad.com. I considered p<0.05 significant. 
 
2.4.4 Allele-specific quantitative RT-PCR. RNA was extracted and cDNA was 
synthesized as above. Quantitative PCR was performed using 1.8μl cDNA, 2uM forward 
and reverse primer, 150nM probe, and 1x Type-it Fast SNP PCR master mix (Qiagen). 
The reaction mix was incubated at 95°C for 5 minutes, followed by 40 cycles of 95°C for 
15 seconds, 67.5°C for 15 seconds, and 72°C for 30 seconds. The long HTT isoform 
allele:total mRNA was calculated using the ΔΔCt method. All primer-probe sets were 
validated as above. I compared HD and control sample averages as above (“Quantitative 
RT-PCR”). 
 
2.4.5 Ethinyl-uridine (EU) pulse chase: in vitro transcription of spike-in. To amplify 
firefly luciferase DNA with the T7 promoter, 10ng template DNA (plasmid with firefly 
luciferase) was combined with 0.3μM forward and reverse primers and 1x Phusion High 
Fidelity PCR Master Mix (NEB). The reaction was incubated at 98°C for 30 seconds; 35 
cycles of 98°C for 15 seconds, 52°C for 10 seconds, and 72°C for 20 seconds; and 72°C 
for 1 minute. The reaction was run on a 1% agarose gel to ensure there was only one 
product and then cleaned with the Promega PCR Purification Kit. T7 RNA polymerase 
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(Promega) performed in vitro transcription. Briefly, 1μg of the firefly PCR product was 
added to a reaction with 1x transcription buffer; 1μl RNAseOut (Thermo Fisher 
Scientific); 0.5mM each of rCTP, rATP, and rGTP; 0.48mM rUTP; 0.02mM E-UTP 
(Jena Bioscience); and 1μl T7 RNA polymerase. The reaction was incubated for 2 hours 
at 37°C, and then treated with RQ1 DNase (Promega). In vitro transcripts were purified 
on Centrispin 20 columns (VWR). To precipitate the purified transcripts, one-tenth 
volume 3M sodium acetate and one volume of phenol chloroform were added, and the 
reaction was vortexed for one minute followed by centrifugation at 12,000g for 10 
minutes. One volume of chloroform was added to the top layer, and the mixture was 
vortexed and centrifuged again. The top layer was kept, 2.5 volumes of ethanol and 4μg 
glycogen were added, and the RNA was precipitated overnight at -20°C. The mixture was 
then centrifuged at 12,000g for 40 minutes at 4°C. The pellet was washed with 70% 
ethanol, spun 10 minutes at 12,000g and 4°C, and resuspended in water. In vitro 
transcripts were Bioanalyzed (Agilent) to ensure a single product. 
 
2.4.6 Ethinyl-uridine (EU) pulse chase. I modified the Click-iT Nascent RNA Capture 
Kit (Life Technologies) as follows. SH-SY5Y cells were pulsed in 200μM EU for 14 
hours and then chased by two washes with PBS before addition of unmodified media. 
Cytoplasmic RNA fractions were collected by lysing cells 10 minutes in hypotonic lysis 
buffer (20mM Tris-HCl, 15mM NaCl, 10mM EDTA, 0.5% NP-40, 0.1% Triton-X-100) 
followed by centrifugation at 1,200g for 10 minutes at 4°C. To extract total cytoplasmic 
RNA, the supernatant was incubated at 42°C for one hour with 1% SDS and 200μg/ml 
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Proteinase K (Ambion) and then ethanol-precipitated as above. The RNA was treated 
with TurboDNAse (Ambion) and cleaned on Clean and Concentrator columns (Zymo). 
Five micrograms RNA was biotinylated per kit instructions with the addition of 0.02ng 
EU-containing firefly spike-in RNA per reaction, and RNA was ethanol-precipitated as 
above. Beads pulled down 4μg RNA as instructed with the exceptions 10% 
trimethylamine was used instead of Click-iT RNA binding buffer in the RNA binding 
reaction, and beads were ultimately resuspended in 25μl 50mM Tris-HCl instead of wash 
buffer 2. SuperScript IV (Invitrogen) reverse transcribed captured RNA in a 50μl reaction 
with 800rpm shaking and the universal reverse transcription primer. Quantitative PCR 
was then performed as above (“Quantitative RT-PCR”). 
 
2.4.7 Cell fractionation. Cytoplasmic RNA fractions were collected by lysing cells 10 
minutes in hypotonic lysis buffer (20mM Tris-HCl, 15mM NaCl, 10mM EDTA, 0.5% 
NP-40, 0.1% Triton-X-100) followed by centrifugation at 1,200g for 10 minutes at 4°C. 
To extract RNA, the supernatant (cytoplasmic) or pellet (nuclear) was incubated at 42°C 
for one hour with 1% SDS and 200μg/ml Proteinase K (Ambion) and then ethanol-
precipitated as above. The RNA was treated with TurboDNAse (Ambion) and submitted 
to quantitative RT-PCR as above (“Quantitative RT-PCR”). The ratio of cytoplasmic to 
nuclear expression of each isoform was compared by Anova with Tukey’s multiple 
comparison test. 
 
2.4.8 PolyA tail length assay. RNA was extracted with Trizol (Ambion), treated with 
 65 
TurboDNAse (Ambion), and cleaned with Clean and Concentrator columns (Zymo). I 
then used the PolyA Tail Length Assay (Affymetrix) to add GI tails to mRNA. Tailed 
mRNAs were reverse transcribed by SuperScript IV (Invitrogen) from the polyA tail 
universal reverse primer (see Table 2.2). The short, mid, and long isoform forward 
primers were used with the isoform specific universal reverse primer to amplify the 
polyA tail. PCR products were resolved on a 2.5% agarose, 1x TAE gel. The bands were 
extracted using the QIAquick Gel Extraction Kit (Qiagen) and Sangar sequenced with the 
forward and reverse primers to ensure isoform PCR specificity. 
 
2.4.9 MicroRNA and RNA binding protein target site prediction. I used the CLIPdb 
and starBase v2.0 browsers to identify RNA binding proteins that interact with the HTT 
3′UTR 193,194. I included brain-expressed RNA binding proteins binding at sites 
represented by more than five reads. Brain expression was confirmed with the human 
protein atlas, www.proteinatlas.org 
195
. To identify predicted microRNA binding sites in 
the HTT 3′UTR, I used TargetScanHuman version 7.0191. I identified brain-expressed 
microRNAs with predicted high-affinity binding sites (7mer-1A, 7mer-m8, 8mer).  Brain 
expression was confirmed with miRmine Human miRNA Expression Database 
196
. 
 
2.4.10 MicroRNA transfection. SH-SY5Y cells were transfected with microRNA 
mimics 137, 221, or both (Dharmacon) using Lipofectamine RNAimax transfection 
reagent (Invitrogen) per manufacturer’s instructions. After 72 hours, RNA was collected 
and submitted to quantitative RT-PCR of HTT isoforms as above (“Quantitative RT-
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PCR”). 
 
Table 2.2 Primers used in chapter 2 
(AS=allele-specific, NAS=non allele-specific, IS=isoform specific) 
Primers (5′-3′)   
Target Forward Reverse 
(NAS) HTT long 3′UTR  ATGGATGCATGCCCTAAGAG CAGTCTCCGATGAGCACAGA 
(NAS) total HTT CATGGTGGGAGAGACTGTGA CAAAGAGCACTTCTGCCACA 
(AS) HTT long 3′UTR  AAGTGGATTCTGGATGGCCG ACATGACAGTCGCCAACCTT 
(AS) total HTT GTGACCAGGTCCTTTCTCCTG TGTTCCCAAAGCCTGCTCAC 
(IS) HTT long 3′UTR  GGAAGGACTGACGAGAGATG ACGCATCTATGCGCATATCG 
(IS) HTT short 3′UTR  
(IS) HTT mid 3′UTR  
AGCAGGCTTTGGGAACACTG 
GTGGCAAGCACCCATCGTAT 
ACGCATCTATGCGCATATCG 
ACGCATCTATGCGCATATCG 
short HTT polyA tail TAGACACCCGGCACCATTCT ACGCATCTATGCGCATATCG 
long HTT polyA tail 
mid HTT polyA tail 
GGAAGGACTGACGAGAGATG 
GGCTGTGGGGAGATTGCTTT 
ACGCATCTATGCGCATATCG 
ACGCATCTATGCGCATATCG 
short HTT -polyA tail TAGACACCCGGCACCATTCT CGTTAAAATTAATCTCTTTACTG 
mid HTT -polyA tail GGCTGTGGGGAGATTGCTTT CCAAACAATTCTACCCTGGT 
long HTT -polyA tail GGAAGGACTGACGAGAGATG GATGGTTTCCATTTTTTTCCTTT 
firefly luciferase qRT-
PCR 
TGATCAAGTACAAGGGCTACCA GCTGCAGCAGGATAGACTCC 
 
Probes (5′-3′) 
  
(AS) HTT long 3′UTR  TCTGCTTGC(C/T)GACTGGCT  
(AS) total HTT CCTGCTGGTTGTTGCCAGGTTG  
 
Reverse transcription primers (5′-3′) 
 
Isoform-specific ACGCATCTATGCGCATATCGTTTTTTTTTTTTTTT 
PolyA tail length assay ACGCATCTATGCGCATATCGCCCCCCCCTTTT 
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CHAPTER III: WIDESPREAD CHANGES IN 3′ ISOFORM ABUNDANCE ARE 
A FEATURE OF HD PATHOLOGY 
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Preface 
 The work presented in this chapter is accepted at Cell Reports as manuscript 
“Alterations in mRNA 3′UTR isoform abundance accompany gene expression changes in 
human Huntington’s disease brains” by Romo, Ashar-Patel, Pfister, and Aronin. 
 This work was a collaborative effort. Ami Ashar-Patel developed the PAS-seq 
protocol. Yasin Kaymaz and Jeff Bailey provided advice on PAS-seq data analysis. 
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3.1 Summary 
Although many genes exhibit expression and splicing differences in HD, 3′UTR 
isoform expression changes have not been investigated
117,138,173,180
. 3′UTR length is 
important for mRNA localization, stability, and translation
132
. Many mRNAs use 3′UTR 
alternative polyadenylation to achieve tissue-specific expression and function
62,84,89
. Long 
mRNA isoforms contain binding sites for trans-acting factors such as microRNAs that 
exert dynamic changes in steady-state mRNA levels
87
. Ubiquitously expressed genes, like 
HTT, are the most likely to use alternative polyadenylation to alter mRNA expression in 
the brain
37,84
. Changes in mRNA 3′UTR length occur in Parkinson’s disease, cancer, and 
myotonic dystrophy, another repeat expansion disease
110,115,178
. In chapter II, I found the 
abundance of HTT 3′UTR isoforms changes in disease. The change arises from both the 
wild-type and mutant alleles, suggesting the cause is a trans factor. If so, other mRNAs 
besides HTT may change their isoform abundances in HD. I sought to determine if 
alterations in 3′UTR length are a feature of HD. 
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3.2 Results 
3.2.1 Many other genes exhibit changes in isoform abundance in HD motor cortex.  
I studied whether alterations in isoform expression are unique to HTT mRNA, or 
features of many mRNAs in HD. To assay transcriptome-wide isoform expression, I 
performed PAS-seq on motor cortex from grade 1 HD brains (n=6) versus controls (n=5), 
and cerebellum from grade 2-4 patient brains (n=9) versus controls (n=7). I identified 
genes with multiple 3′UTR isoforms, and normalized isoform expression to gene 
expression (see methods). I compared the normalized isoform expression between HD 
and control samples. 
 PAS-seq uses oligo(dT) to capture polyA tails during reverse transcription. 
Oligo(dT) also anneals to genomic polyA stretches. These genomic sites are artefacts. 
Artefactual polyA sites can lead to overestimation of the number of alternatively 
polyadenylated genes
185
. I remove these genomically-primed reads from my data. To 
validate my analysis, I compared the number of alternatively polyadenylated genes 
identified by PAS-seq to that that identified by the 3Pseq 3′ sequencing method, which 
avoids oligo(dT) priming
61
.  I found 33% of genes in the motor cortex and 30% in the 
cerebellum display alternative polyadenylation, with over half exhibiting two 3′UTR 
isoforms (Fig. 3.1). This percentage is similar to that obtained via 3Pseq. Consistency 
with 3Pseq data indicates PAS-seq accurately captured reads primed from mRNA polyA 
tails while excluding reads primed from genomic polyA regions. As previously reported 
in brain tissue, I found long isoforms are more abundant than short isoforms in 
cerebellum and motor cortex
86
. 
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In the motor cortex, 11% of 2,164 alternatively polyadenylated genes showed a 
significant (false discovery rate<10%) change in abundance of at least one isoform in HD 
(p<0.01) (Fig. 3.2A). Many isoform abundances changed over 25% in HD motor cortex 
versus controls, indicating a major shift in isoform expression for the corresponding gene 
(Fig. 3.2B). In the cerebellum, none of the alternatively polyadenylated genes showed a 
significant (false discovery rate <10%) change in abundance of at least one isoform (Fig. 
3.2C). The false discovery rate threshold corrects for false-positives due to multiple 
testing, but may reject true positives. To allow comparison of isoform changes between 
motor cortex and cerebellum, I also included a more sensitive p-value threshold (p<0.01). 
Using this threshold, thirteen percent of alternatively polyadenylated genes exhibit 
isoform changes in HD motor cortex, whereas five percent of genes exhibit changes in 
cerebellum. Isoform abundance changes in the cerebellum were not as large as in the 
motor cortex (Fig. 3.2D). These results indicate that there are widespread isoform 
changes in HD motor cortex that alter the 3’UTR isoform abundances for many genes, 
whereas changes in the cerebellum are negligible. 
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Figure 3.1. Isoform number distributions match previous studies. (A) Histogram of 
number of 3′UTR isoforms per gene in cerebellum. I included isoforms represented in at 
least two samples (B) Histogram of number of isoforms per gene in motor cortex. 
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Figure 3.2. Transcriptome-wide PAS-seq analysis identifies a large subset of genes 
with 3′UTR isoform changes in HD motor cortex.  
(A) Scatter plot of PAS-seq reads from control (n=5) and HD (n=6) motor cortex. Each 
dot represents a unique 3′UTR isoform expressed in at least five HD and control samples. 
Shown is the number of reads mapping to the isoform divided by the total reads mapping 
to the gene 3′UTR (isoform fraction). Orange dots indicate isoforms with p<0.01, 
whereas red dots indicate isoforms with adjusted p<0.1 (false discovery rate<10%). (B) 
Volcano plot of reads from control and HD motor cortex, colors as in A. The percent 
change is calculated as the difference in the isoform fraction between HD and control 
samples multiplied by 100. (C) Scatter plot of PAS-seq reads from control (n=7) and HD 
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(n=9) cerebellum, as in A. Green dots indicate isoforms with p<0.01. (D) Volcano plot of 
reads from control and HD cerebellum, colors as in C. 
 
Neurons die and glia proliferate in the HD brain
29
. Although neuronal loss is 
limited to around 10% in grade 1 motor cortex, it is possible some or all isoform changes 
I see are due to changes in cell populations
183
. I found isoform abundance is highly 
correlated (r=0.87) between the motor cortex and cerebellum despite the different cell 
milieu and limited neuronal loss in the cerebellum (Fig 3.3). The correlation of isoform 
abundance between brain regions suggests isoform abundances do not greatly differ 
between cell types, and a 10% neuronal loss is unlikely to cause substantial shifts in 
isoform abundance. Previous studies that used HD caudate, which suffers extensive 
neuronal loss (50-95%), have demonstrated mRNA expression is similar in HD caudate 
tissue and HD caudate neurons
138
. These results suggest the isoform changes I observe in 
HD motor cortex are not solely due to neuronal loss. 
To determine whether genes with significant (p<0.01) isoform changes shifted 
towards longer or shorter mRNA 3′UTR isoforms, I calculated a weighted change (see 
methods). If the weighted change is positive, the gene shifts towards longer mRNA 
isoforms in HD patients, whereas if it is negative, the gene shifts towards shorter 
isoforms. I found 129 genes shift towards longer isoforms in HD motor cortex, whereas 
110 genes shift towards shorter isoforms (Fig. 3.4A). In the cerebellum, I found 31 genes 
shifted to longer isoforms, whereas 83 shifted to shorter isoforms (Fig. 3.4B). Thus 
isoform shifts are gene-specific, and there is no generalized shift towards longer or 
shorter isoforms in HD.  
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Figure 3.3. The expression of most isoforms and genes is highly correlated between 
cerebellum and motor cortex. 
 (A) Scatter plot of PAS-Seq reads from HD motor cortex (MCx, n=6) and cerebellum 
(CB, n=9). Each dot represents a 3’UTR isoform. Shown is the number of reads mapping 
to the isoform divided by the total reads mapping to the gene 3′UTR, and the Pearson 
correlation coefficient (r) of isoform expression between the brain regions. (B) Scatter 
plot of PAS-Seq reads as in A, from control motor cortex (n=5) and cerebellum (n=7). 
(C) Scatter plot of PAS-Seq reads from HD motor cortex (MCx, n=6) and cerebellum 
(CB, n=9). Each dot represents a gene. Shown is the total number of reads mapping to the 
gene normalized to sequencing depth (normalized counts), and the Pearson correlation 
coefficient (r) of gene expression between the brain regions. (D) Scatter plot of PAS-Seq 
reads as in C, from HD motor cortex (n=5) and cerebellum (n=7). 
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Figure 3.4. There is no global shift to longer or shorter 3′UTR isoforms in HD 
patient brains.  
(A) Heat map of the weighted change (see methods) of genes with one or more isoform 
differentially expressed in patient motor cortex (p<0.01). A positive number indicates the 
gene shifts towards longer isoforms in HD, whereas a negative number indicates the gene 
shifts towards shorter isoforms in HD. (B) Heat map of genes with one or more isoform 
significantly differentially expressed in patient cerebellum, as in A. 
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I compared significant (p<0.01) isoform shifts in the motor cortex and cerebellum 
to look for common changes. Only 11 genes exhibit mRNA 3′UTR isoform shifts in both 
the motor cortex and cerebellum (Fig. 3.5A, purple). Of these, 9 showed opposite 
changes in the motor cortex, with 7 of the 9 shifting towards shorter isoforms in the 
cerebellum and longer isoforms in the motor cortex. This finding indicates that isoform 
changes in HD are region-specific. 
 
3.2.2 Genes with isoform shifts are involved in pathways associated with HD 
pathogenesis. 
To identify affected pathways, I performed gene ontology analysis on genes with 
significant (p<0.01) isoform shifts. I found genes that shift to longer 3′UTR isoforms are 
enriched for different pathways compared to genes that shift to shorter isoforms (Fig. 
3.5B). Several of these pathways have been reported to be enriched among genes 
differentially expressed in HD, including cytokine signaling and production, RNA pol2 
transcription, translation, calcium signaling, vesicle-mediated transport, microtubule 
organization, and DNA binding
138,180
. Some enriched pathways are thought to be 
involved in HD pathogenesis, including calcium signaling, cytokine signaling, histone 
acetylation, transcription factor binding, axonal transport, synaptic vesicle localization, 
dendritic spine morphogenesis, microtubule organizing, and phagocytic vesicles
197–201
. 
These results suggest aberrant 3′UTR isoform expression may influence pathogenesis in 
these disease pathways.  
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Figure 3.5. HD-associated pathways are enriched among genes with isoform 
changes.  
(A) Comparison of gene weighted changes between patient versus control motor cortex 
(MCx) and cerebellum (CB). Green dots have significant changes in HD cerebellum, 
orange dots have significant changes in HD motor cortex, and purple dots have both 
(p<0.01). (B) Gene ontology analysis of genes exhibiting significant (p<0.01) shifts to 
longer (long) or shorter (short) isoforms in HD motor cortex (MCx) and cerebellum (CB). 
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3.2.3 Many genes are differentially expressed in HD motor cortex.  
 Widespread gene expression changes are reported in the cortex of late-stage 
Huntington’s disease patients180. I sought to determine if the extensive 3′UTR isoform 
changes in HD motor cortex co-occur with gene expression changes. PAS-seq captures 
polyadenylated mRNA isoforms. To measure steady-state gene expression, I summed all 
PAS-seq reads, or isoforms, from each gene (see methods). Consistent with previous 
studies, many genes were differentially expressed in HD patient motor cortex relative to 
control motor cortex (false discovery rate<10%, 1.5-fold change) (Fig. 3.6A)
138,180
. Of 
differentially expressed genes, 700 exhibited increased expression in HD motor cortex, 
whereas 1008 exhibited decreased expression (Fig. 3.7A). The percent of detected genes 
exhibiting expression changes is identical to the percent of alternatively polyadenylated 
genes exhibiting isoform changes (11%), indicating isoform changes are proportional to 
gene expression changes in HD motor cortex. In contrast, only 1% of genes are 
differentially expressed (false discovery rate<10%, 1.5-fold change) in patient 
cerebellum, with 2.5% making the unadjusted p-value cutoff (Fig. 3.6B). Of differentially 
expressed genes, 89 increased expression in patient cerebellum whereas 64 decreased 
(Fig. 3.7B). This percent is also consistent with PAS-seq, which found 5% of genes made 
the unadjusted p-value cutoff for isoform changes. Thus, isoform changes accompany 
gene expression changes in the HD motor cortex, whereas isoform and gene expression 
changes are minimal in the cerebellum. 
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Figure 3.6. Gene expression analysis identifies a large subset of genes with 
expression changes in HD motor cortex. 
(A) Scatter plot of PAS-seq reads from control (n=5) and HD (n=6) motor cortex. Each 
dot represents the normalized expression of a gene. Orange dots indicate isoforms with 
p<0.01, whereas red dots indicate isoforms with adjusted p<0.1 (false discovery 
rate<10%). (B) Scatter plot of PAS-seq reads from control (n=7) and HD (n=9) 
cerebellum, as in A. Green dots indicate isoforms with p<0.01, whereas blue dots indicate 
isoforms with adjusted p<0.1 (false discovery rate<10%).  
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Figure 3.7. Most differentially expressed genes are down-regulated in HD brains. 
(A) Heat map of genes significantly differentially expressed in patient motor cortex (false 
discovery rate<10%). Shown are HD normalized read counts divided by control 
normalized read counts. (B) Heat map of genes significantly differentially expressed in 
HD cerebellum (false discovery rate<10%), as in A. 
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3.2.4 Many isoforms and genes switch expression between HD grade 1 and grade 2. 
I compared my gene expression results to those of previous HD patient studies 
that used microarrays of motor cortex and cerebellum or RNA sequencing from 
prefrontal cortex
138,180
. I found many genes reported differentially expressed in HD 
patient brains were also differentially expressed in my data. However, some genes 
previously reported to increase in HD motor cortex compared to controls were decreased 
in my samples, and some genes previously reported to decrease were increased in my 
samples. Quantitative PCR of three of these genes validated my PAS-seq results (Fig. 
3.8). In contrast, my cerebellum data largely agreed with previous studies. I speculated 
that these discrepancies arose because previous studies used motor cortex from a mixture 
of HD grades, whereas I used motor cortex from grade 1 brains exclusively.  
To investigate whether gene expression changes with disease progression, I 
performed PAS-seq on grade 2 HD motor cortex (n=4) (Fig. 3.9). Although my statistical 
power was limited by small sample size, I found the magnitude of significant 3′UTR 
isoform changes was greater than in grade 1, with most genes (68%) shifting to longer 
isoforms (Fig. 3.9A and D, 3.10A). PAS-seq revealed three outlier genes with extreme 
3′UTR isoform shifts in grade 2 motor cortex: NDFIP1, AP1G1, and CTSB (Fig. 3.9A,B). 
NDFIP1 protein plays a vital role in healing cortical injury, while AP1G1 is essential for 
formation of clathrin-coated vesicles
202,203
. Axonal transport of these vesicles is impaired 
in HD neurons
204
. Interestingly, CTSB protein was recently found to mediate the 
beneficial effect of exercising on hippocampal neurogenesis, an effect that is lost in 
mouse models of HD
205,206
.  
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Figure 3.8. qPCR validates select PAS-
Seq significant gene expression changes. 
Grade 1 motor cortex qPCR validation of 
three differentially expressed genes 
previously reported down-regulated 
(CAMKK2) or up-regulated (GJA1, 
GFAP) in mixed-grade HD motor cortex. 
Shown is average expression across 
samples (n=3-4 per group) with standard 
deviation. *, **, and *** signify p<0.05, 
0.005, and 0.0005. 
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Figure 3.9. Many isoforms and genes are differentially expressed in motor cortex 
from HD patient grade 2 brains. 
(A) Scatter plot of PAS-Seq reads from control (n=5) and HD (n=4) grade 2 motor 
cortex. Each dot represents a unique 3’UTR isoform expressed in at least four HD and 
control samples. Shown is the number of reads mapping to the isoform divided by the 
total reads mapping to the gene 3′UTR (isoform fraction). Orange dots indicate isoforms 
with p<0.01, while red dots indicate isoforms with adjusted p<0.1 (false discovery 
rate<10%). (B) Volcano plot of reads from control and HD grade 2 motor cortex, colors 
as in A. The percent change is calculated as the difference in the isoform fraction 
between HD and control samples. (C) Scatter plot of PAS-Seq reads from control and HD 
grade 2 motor cortex. Each dot represents a gene. Shown is the total number of reads 
mapping to the gene normalized to sequencing depth (normalized counts). Orange dots 
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indicate isoforms with p<0.01, while red dots indicate isoforms with adjusted p<0.1 (false 
discovery rate<10%).  
 
In contrast to motor cortex from grade 1 samples, the majority of genes (86%) 
exhibited decreased expression in motor cortex from grade 2 samples (Fig. 3.9C). I 
identified eight genes with increased expression in previous HD studies that had 
significantly decreased expression in my grade 1 samples, and six genes with decreased 
expression in previous HD studies that had significantly increased expression in my grade 
1 samples
138
. Eleven of these genes switched gene expression between grade 1 and grade 
2 HD motor cortex (i.e., from increased expression relative to controls to decreased 
expression), and the other three moved from greater than 1.5-fold change to less than 1.5-
fold change (Table 3.1; Fig. 3.10B, gold dots). Surprisingly, many other genes with 
significantly increased expression in grade 1 cortex exhibit significantly decreased 
expression in grade 2 cortex, and vice versa (Fig. 3.10C, light blue in quadrants II and 
IV). These results suggest isoform and gene expression changes in HD motor cortex are 
grade-specific, and gene expression studies should not combine several grades of HD 
cortex. 
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Figure 3.10. Many isoforms and genes switch expression between HD grade 1 and 
grade 2. 
(A) Comparison of gene isoform weighted changes and differential expression (DE) log 2 
fold changes in HD versus control grade 2 motor cortex. The weighted change is the 
difference in the average weighted isoform ratio between HD and control samples (see 
methods). Green dots have significant (p<0.01) isoform changes, orange dots have 
significant expression changes (p<0.01), and red dots have both. (B) Comparison of gene 
weighted changes in patient versus control grade 1 motor cortex (MCxgr1) and grade 2 
motor cortex (MCxgr2), calculated as in A. (C) Comparison of gene expression log 2 fold 
changes in motor cortex grade 1 and grade 2 motor cortex. Orange dots were previously 
reported to have opposite expression changes than in my grade 1 data. 
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Table 3.1. Top genes with opposite direction expression changes in my data 
compared to previous studies.   
 
  MCxgr1 L2FC MCxgr2L2FC 
ATP2B2 1.36 -0.10 
EGR4 1.03 -0.41 
CAMKK2 0.67 -0.50 
SORT1 0.66 -0.22 
PSEN1 0.59 -0.32 
LAPTM4B 0.46 -0.42 
SOX9 -0.87 0.39 
FGF2 -1.12 -0.54 
SLC14A1 -1.44 0.29 
MT1H -1.49 0.40 
SLC1A3 -1.51 -0.12 
CD44 -1.57 -0.53 
MT1G -1.68 0.35 
GJA1 -1.83 0.84 
 
Shown are the log2 fold changes (L2FC) in motor cortex (MCx) from grade 1 (gr1) and 
grade 2 (gr2) HD patient brains for fourteen genes. 
 
 
3.2.4 Most genes with isoform changes in HD are not differentially expressed. 
To determine if genes with isoform changes also exhibit expression changes, I 
compared gene expression to isoform expression for all alternatively polyadenylated 
genes in the motor cortex and cerebellum using a significance cutoff of p<0.01 (Fig. 
3.11A,B). In the motor cortex, only 17% of genes with isoform shifts also exhibit gene 
expression changes (Fig. 3.11A, red). Of genes exhibiting isoform and gene expression 
changes, I found no association between isoform shift and gene expression direction, with 
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about equal numbers of genes in all four quadrants. This dissociation of isoform and gene 
expression is consistent with studies showing the association between 3′UTR length and 
isoform stability is gene-specific
112
. In the cerebellum, only 4% of genes with significant 
isoform changes are also differentially expressed (Fig. 3.11B, red). Of these, all are 
shifted towards shorter isoforms with two exhibiting increased expression and two 
exhibiting decreased expression. These results indicate that most genes with isoform 
changes are not differentially expressed in HD motor cortex and cerebellum.  
 
 
 
 
Figure 3.11. Most genes with 3′UTR isoform changes do not exhibit expression 
changes in HD.  
(A) Comparison of gene isoform weighted changes (see methods) and differential 
expression (DE) log 2 fold changes in HD versus control motor cortex. Green dots have 
significant isoform changes in HD, orange dots have significant expression changes in 
HD, and red dots have both (p<0.01). (B) Comparison of gene isoform weighted changes 
and expression log 2 fold changes in HD versus control cerebellum, as in A. 
 
 
 89 
 
I compared gene expression between the motor cortex and cerebellum to see if 
there is overlap in differentially expressed genes. I found sixteen (11%) genes 
differentially expressed in the cerebellum are also differentially expressed in motor 
cortex (Fig. 3.12A, light blue). Of these, eleven are inversely expressed in motor cortex. I 
performed gene ontology analysis to identify pathways enriched (p<0.01) among genes 
with increased or decrease expression in the motor cortex, cerebellum, or both (Fig. 
3.12B). 
My analysis identified several pathways previously reported to be enriched among 
genes differentially expressed in HD motor cortex: CNS development, protein 
localization, extracellular exosome, fatty acid biosynthesis, and regulation of TNF 
signaling
138,180
. I provide a more detailed gene ontology analysis than previous studies, 
separating genes into categories based on region and direction of change. My data reveals 
many pathways enriched in both genes with decreased expression exclusively in motor 
cortex, and genes with increased expression exclusively in cerebellum. Some of these 
pathways, including protein folding and ubiquitination, are vital for clearance of the 
mutant HTT protein. Region-specific regulation of these processes may be related to 
region-specific pathology. In contrast, genes with expression changes in both motor 
cortex and cerebellum are enriched for immune and stress responses, suggesting 
dysfunction of these pathways is not region-specific. 
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Figure 3.12. Pathways enriched among differentially expressed genes are region-
specific.  
(A) Comparison of gene expression log-2 fold changes (in motor cortex (MCx) and 
cerebellum (CB). Red dots have significant expression changes in HD motor cortex, blue 
dots have significant changes in HD cerebellum, and light blue have both (false discovery 
rate<10%). (B) Gene ontology analysis of genes exhibiting significant (false discovery 
rate<10%) expression changes in HD motor cortex (MCx) and cerebellum (CB). 
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I sought to determine if isoform and gene expression changes are associated with 
common cell pathways. I found several ontology categories enriched among genes with 
isoform changes and genes with expression changes including mRNA 3′UTR binding, 
cell junction, ubiquitination, mRNA binding, and protein transport (Fig. 3.5B, 3.12B). 
Within each category, genes with isoform differences and genes with expression changes 
do not overlap; i.e., the same gene does not exhibit aberrant isoform and gene expression. 
These results indicate that isoform alterations and gene expression changes are separate, 
but they may affect common processes in HD brains. 
 
3.2.5 Most genes do not show an increase in non-UTR isoforms in HD. Many mRNAs 
change their splicing patterns in HD
117,173
. These changes may lead to increases in non-
3′UTR isoforms, including isoforms that are misspliced or terminated early, such as the 
truncated HTT isoform
40
. To identify non-UTR isoforms, I separated and summed reads 
mapping to the 3′UTR or to the open reading frame of every gene. I then compared the 
fraction of non-3′UTR reads in disease and control samples. I found very few genes (2%) 
with a significant (p<0.01) increase in non-3′UTR reads in both patient motor cortex and 
cerebellum compared to controls, suggesting misspliced transcripts retain the canonical 
3′UTR rather than shifting to non-3′UTR polyA signals. HTT itself was unchanged, as 
expected given the low abundance of the truncated intron one isoform
40
. I did not detect 
the truncated isoform in my data, potentially because PCR of boundary of HTT exon 1 
and intron 1 is difficult due to its GC-rich content
207
.  
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3.3 Discussion 
HD brains exhibit extensive alterations in mRNA expression and splicing
117,138
. I 
studied whether widespread mRNA 3′UTR isoform changes occur in HD. Using PAS-
seq, I identified a large subset of genes with mRNA 3′UTR isoform shifts in HD motor 
cortex.  Genes with isoform changes were involved in pathways known to be aberrant in 
HD. In contrast, the cerebellum, which is less affected in HD, exhibited minimal changes. 
As expected, many genes were differentially expressed in HD motor cortex. 
Differentially expressed genes were mostly separate from genes with isoform changes, 
although they were involved in similar pathways.  
 This is the first study identifying widespread 3′UTR isoform alterations in HD. I 
expect my results are not due to neuronal loss, as motor cortex from grade 1 and 
cerebellum from grade 2-4 HD brains exhibit minimal cell loss, and isoform abundances 
for most genes are well-correlated between motor cortex and cerebellum. One caveat of 
PAS-seq is that it only detects polyadenylated isoforms.  Neuron cell bodies contain 
deadenylated pools of mRNA
208
.  Thus some isoform differences I detected may be due 
to altered deadenylation in HD. I only investigated changes in terminal 3′UTR isoforms. 
Alternative polyadenylation can also occur in non-canonical 3′UTRs or in introns. 
Finally, some of my post-mortem samples had low RNA integrity.  I found as the RNA 
integrity number (RIN) fell below a score of 3 (see methods), PAS-seq reads shifted 
away from the 3′UTR to the open reading frame, indicating mRNA 3′ end degradation.  
However, I selected only high quality samples for PAS-seq, and RINs were similar 
between HD and control samples.  
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Surprisingly, although my HD grade 1 motor cortex differentially expressed genes 
overlap extensively with previous studies on mixed-grade samples, many show opposite 
changes in my samples
138,180
. I found almost all of these discrepant genes change 
expression between grade 1 and grade 2. Although many genes have increased expression 
in grade 1 motor cortex, few genes show increased expression in grade 2, suggesting loss 
of transcriptional activators, gain of transcriptional repressors, or changes in mRNA 
stability with disease progression.  I found HDAC transcription repressors are enriched 
amongst genes down-regulated in motor cortex from grade 1 but not grade 2 HD brains. 
Decreased expression of these genes may lead to increased transcription in motor cortex 
from grade 1 brains that is lost by grade 2, when HDAC expression normalizes.  
Interestingly, HDAC inhibitors increase neuronal survival in HD models
197
. 
Widespread changes in isoform abundance may lead to aberrant mRNA 
metabolism in HD. Some tandem 3′UTR isoforms exhibit unique localization and 
function. The long but not short 3′UTR isoform of brain-derived neurotrophic factor 
mRNA is translated in dendrites, where the protein is vital for pruning and spine 
enlargement
94
. The long isoform of CD47 mRNA acts as a scaffold for proteins that 
translocate the CD47 protein to the cell membrane, whereas the short isoform localizes 
the protein to the endoplasmic reticulum
97
. Loss of normal mRNA isoform abundance 
can contribute to disease. The alpha synuclein long 3′UTR isoform is preferentially 
localized to mitochondria; increased abundance of the extended alpha synuclein mRNA 
may contribute to mitochondrial dysfunction in Parkinson’s disease115. Several genes 
change their 3′UTR isoform amounts in cancer and myotonic dystrophy110,178. In cancer 
 94 
cell lines, oncogenes shift to shorter isoforms, resulting in increased protein 
production
110
. 
I demonstrate that genes with isoform changes in HD motor cortex are associated 
with pathways disrupted in HD including calcium signaling, cytokine signaling, histone 
acetylation, transcription factor binding, axonal transport, synaptic vesicle localization, 
dendritic spine morphogenesis, microtubule organizing, and phagocytic vesicles. Altered 
metabolism of mRNAs in disease pathways could result in aberrant localization or 
function of proteins implicated in HD pathogenesis. I didn’t see a concerted shift to 
shorter or longer isoforms in HD motor cortex, but studies have shown stability is 
isoform-specific
112
. Proteomic work is necessary to determine if genes with isoform 
changes exhibit alterations in protein abundance, and whether the proteins are involved in 
HD pathology.  
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3.4 Materials and methods 
3.4.1 PAS-seq library preparation. For PAS-seq method including adaptor, primer, and 
barcode sequences, see Ashar-Patel 2017, manuscript in preparation. Briefly, 5-10μg total 
RNA was collected using Trizol (Ambion), and RNA quality was assessed by 
Bioanalyzer (Agilent). RNA was treated with TurboDNAse (Ambion) and cleaned with 
Clean and Concentrator columns (Zymo). Cleaned RNA was fragmented in 1x 
SuperScript III first strand buffer (Invitrogen) at 94°C for 5 minutes 30 seconds and 
immediately placed on ice. SuperScript III (Invitrogen) reverse transcribed fragmented 
RNA from the custom PAS-seq oligo d(T) primer, and 20 minute incubation with RNAse 
I hydrolyzed remaining RNA (Life Technologies). Samples were run on a denaturing 8M 
urea, 10% polyacrylamide gel, and 160-200 nucleotide cDNA fragments were eluted 
overnight in elution buffer (300mM NaCl, 10mM EDTA). Spin-X columns (Corning) 
removed remaining gel pieces, and eluted cDNA was precipitated by incubation with 
50% isopropanol at -20°C for 30 minutes followed by centrifugation at maximum speed 
for 45 minutes at 4°C. The pellet was washed with 70% ethanol and collected by 
spinning at maximum speed for 10 minutes at 4°C. Dried pellets were resuspended in 
water. cDNA was circularized by incubation with CircLigase II (Epicentre) at 60°C for 4 
hours. Phusion polymerase (NEB) amplified the insert and adaptors with PE 1.0 and PE 
2.0 primers (Illumina) by incubation at 98°C for 30 seconds; 14 cycles of 98°C for 5 
seconds, 62°C for 10 seconds, and 72°C for 10 seconds; and a final extension of 72°C for 
2 minutes. The PCR products were run on a non-denaturing 10% polyacrylamide gel. The 
215-254 nucleotide library was extracted and eluted/precipitated as above. Libraries were 
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Bioanalyzed (Agilent) for quality control, and sequenced with single-end 100 base-pair 
sequencing on Illumina HiSeq 2000 or MiSeq instruments. 
 
3.4.2 PAS-seq analysis: isoform and gene expression quantification. I sorted indexed 
reads into samples and removed the barcode and randomer (see Ashar-Patel 2017, in 
preparation). Cutadapt trimmed the 3′ polyA tail and low quality bases (phred<25), 
excluding reads less than 15 nucleotides
209
. I checked the quality of the remaining reads 
using Fastqc (Andrews, S., 2010, http://www.bioinformatics.babraham. 
ac.uk/projects/fastqc) before mapping them to the hg19 or mm10 genome with Bowtie 
210
. Bedtools converted the bam files to bed files and computed the read 3′ end coverage 
of each coordinate (PAS-seq read 3′ ends represent polyA sites) 211. Because the site of 
cleavage and polyA is heterogeneous, I wrote a peak-calling program to combine reads 
within 24 nucleotides of the coordinate with the most 3′ end coverage for each polyA site. 
I used 24 nucleotides because the majority of cleavage events from the same polyA signal 
occur within 24 nucleotides of the most 5’ cleavage site 187. My peak-calling program 
generated slightly different coordinates between samples for the same isoform due to 
small inter-sample variations in isoform 3′ end coverage. I considered isoform peaks 
between samples to be the same if they were within 40 nucleotides of each other, as 40 
nucleotides is the maximum difference between cleavage sites of the same isoform 
187
.  I 
mapped peaks with more than five reads to gene ORF or 3′UTRs, excluding peaks with 
non-unique mapping. For each gene, I defined the 3′UTR as the terminal (most 3′) 
coordinates from the UCSC table browser. I used CleanUpdTSeq to remove genomically-
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primed peaks, a Bayesian classifier that performs better than heuristic methods at 
removing false positives while retaining true positives 
185
. I identified alternatively 
polyadenylated genes as genes with more than one 3′UTR peak. For differential 
expression analysis, I combined all reads mapping to a gene, either the ORF or the 
3′UTR. Raw and processed data can be accessed at http://www.ncbi.nlm.nih.gov 
/geo/query/acc.cgi?acc=GSE96099.  My full bioinformatics pipeline is available in 
Appendix 2. 
 
3.4.3 PAS-seq analysis: HD versus control isoform comparison. I normalized the 
expression of each isoform in alternatively polyadenylated genes by dividing the isoform 
abundance by the total reads mapping to the gene 3′UTR. I compared the normalized 
isoform abundance between HD and control samples using t-tests with or without 
multiple-hypothesis testing correction using the Benjamini-Hochburg procedure. I 
considered an adjusted p-value <0.1 to be significant unless otherwise stated (false 
discovery rate<10%). I did not place a fold or percent change cutoff because small 
changes in isoform abundances of some genes may affect cellular functions. However, 
most (>75%) significantly changing isoforms changed by 5% or more, and those with 
smaller changes tended to be low-abundance isoforms. Only isoforms represented in at 
least five disease and control samples were considered. These and further PAS-seq 
analyses were performed using R 3.3.2 (R Foundation for Statistical Computing, Vienna, 
Austria, URL https://www.R-project.org/). 
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3.4.4 PAS-seq analysis: isoform weighted change. For each gene with a significant 
change in the abundance of at least one isoform, I determined a weighted change. I 
weighed each isoform ratio by the isoform number multiplied by ten. For instance, for a 
gene transcribed into two isoforms of equal abundance (isoform ratios of 0.5), the shorter 
isoform weighted ratio is 5 (0.5 x 10 x 1) whereas the longer isoform weighted ratio is 10 
(0.5 x 10 x 2). I then calculated the difference in the average weighted isoform ratios 
between HD and control samples for the gene. A positive weighted change indicates a 
shift towards longer isoforms in HD samples, whereas a negative weighted change 
indicates a shift towards shorter isoforms in HD samples. 
 
3.4.5 PAS-seq analysis: HD versus control gene expression comparison. The total 
reads mapping to each gene were compared between patients and controls using the 
DESeq2 differential expression package
212
. I considered genes with a fold change greater 
than 50% and false discovery rate <10% (Benjamini Hochburg correction) significantly 
differentially expressed.  
 
3.4.6 Gene ontology analysis. For isoform analysis, the list of genes with significant 
(p<0.01) changes in at least one 3′UTR isoform in HD motor cortex or cerebellum were 
compared to the background total expressed APA genes in each region using Panther 
gene ontology analysis
213
. I considered categories significantly enriched if they had more 
than five genes, enrichment greater than 1.5 fold compared to background, and p value 
less than 0.01. For gene expression analysis, the list of genes with significant (false 
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discovery rate<10%) expression changes in HD motor cortex or cerebellum were 
compared to the background total expressed genes in each region using Panther gene 
ontology analysis as above. 
 
3.4.7 PAS-seq validation RT-qPCR. Total RNA was extracted using Trizol (Ambion), 
and RNA quality was assessed by Bioanalyzer (Agilent). RNA was treated with 
TurboDNAse (Ambion), and cDNA was synthesized from 2μg total RNA using 
SuperScript IV (Invitrogen) with oligo d(T)20 priming per manufacturer’s instructions. 
Quantitative PCR was performed with 1.8μl cDNA, and QuantiFast SYBR green master 
mix (Qiagen). The CAMKK2, GJA1, and GFAP PrimePCR Assay primer mixes (Biorad) 
were used at 1x in the PCR reaction. Reactions were incubated at 95°C for 5 minutes, 
followed by 40 cycles of 95°C for 10 seconds and 60°C for 30 seconds on a StepOnePlus 
Real-Time PCR System (Thermo Fisher Scientific). All primers were validated by 
relative standard curve, and primer pairs amplified targets with 85-115% efficiency in the 
linear range. I verified primer specificity by running qPCR products on a 2% agarose, 1x 
TAE gel, extracting the bands using the QIAquick Gel Extraction Kit (Qiagen), and 
Sangar sequencing the bands with the forward and reverse PCR primers.  
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Table 3.2 Primers used in chapter 3 (AS=allele-specific, NAS=non allele-specific, IS=isoform specific 
Primers (5′-3′)   
Target Forward Reverse 
CAMKK2 PrimePCR Assay primer mix (Biorad) 
GJA1 PrimePCR Assay primer mix (Biorad) 
GFAP PrimePCR Assay primer mix (Biorad) 
GAPDH GAGTCAACGGATTTGGTCGT TTGATTTTGGAGGGATCTCG 
Reverse transcription primers (5′-3′)  
Isoform-specific ACGCATCTATGCGCATATCGTTTTTTTTTTTTTTT 
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CHAPTER IV: RNA BINDING PROTEINS MAY AFFECT 3′UTR ISOFORM 
ABUNDANCE 
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Preface 
 The work presented in this chapter is accepted at Cell Reports as manuscript 
“Alterations in mRNA 3′UTR isoform abundance accompany gene expression changes in 
human Huntington’s disease brains” by Romo, Ashar-Patel, Pfister, and Aronin. 
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4.1 Summary 
 RNA binding proteins mediate alternative polyadenylation, and altered expression 
of RNA binding proteins can lead to shifts in 3′UTR length55. There are many examples 
of altered expression of RNA binding proteins modulating alternative polyadenylation 
site selection. Increased levels of 3′ processing factor CstF-64 promote proximal polyA 
sites, whereas knockdown of CFIm68 also shifts mRNAs towards proximal polyA 
sites
60,71,72
. RNA binding proteins PTB, SXL, and PABPN1 promote distal polyA site 
usage
74,75,79
. Similarly, knockdown of U1 snRNP and ELL2 results in shifts to proximal 
polyA sites
64,81
. 
As many genes are differentially expressed in HD, I reasoned altered expression 
of an RNA binding protein could cause alterations in 3′UTR isoforms. I identified 
CNOT6 as an RNA binding protein differentially expressed in HD motor cortex. 
Knockdown of CNOT6 in wild-type fibroblasts results in HTT 3′UTR isoform shifts 
similar to those seen in HD fibroblasts and motor cortex.  In addition, the 3′UTR 
isoforms of SECISBP2L, another gene with isoform shifts in HD, exhibit shifts similar to 
those in HD motor cortex. 
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4.2 Results 
4.2.1 Decreasing expression of the RNA binding protein CNOT6 leads some genes to 
change isoform abundance. A change in the expression of an RNA binding protein may 
lead to changes in isoform abundance by altering isoform production rates during 
alternative polyadenylation, or by affecting isoform decay rates post-transcriptionally. To 
identify candidate RNA binding proteins, I searched for genes differentially expressed in 
HD motor cortex with the RNA binding protein GO-term (Fig. 4.1). Of those, twenty 
were involved in mRNA alternative polyadenylation or stability. I reasoned an RNA 
binding protein responsible for HTT isoform shifts would show opposite expression in 
motor cortex and cerebellum. Of the nine fitting that description, two were subunits of the 
Ccr4-not complex that plays a widepread role in mRNA metabolism
214,215
. Of the two, 
CNOT6 is more differentially expressed in HD motor cortex and cerebellum.  CNOT6 is 
the subunit of the Ccr4-not complex that catalyzes deadenylation of mRNAs. Because 
CNOT6 is increased in HD cerebellum but decreased in motor cortex, I expected mRNAs 
targeted by CNOT6 to exhibit opposite changes in the cerebellum and motor cortex. For 
instance, if a CNOT6 target shifts to shorter 3′UTR isoforms in HD motor cortex, I 
expect it to change to longer isoforms in HD cerebellum. Indeed, 82% of genes with 
isoform alterations in motor cortex and cerebellum, including HTT, exhibit opposite 
isoform deviations.  
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Figure 4.1. RNA binding proteins differentially expressed in HD motor cortex include Ccr4-
not complex components CNOT6 and CNOT7. Algorithm to identify proteins that might cause 
3′UTR isoform changes in HD patient brains identified CNOT6 and CNOT7, members of the 
multi-functional Ccr4-not complex that plays a role in many aspects of RNA metabolism. . 
Numbers are fold changes (FC) in mRNA expression between HD and control motor cortex 
(MCx) or cerebellum (CB). 
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To determine if changes in CNOT6 expression exert changes in isoform 
expression, I transfected control human fibroblasts with siRNAs targeting CNOT6 or an 
off-target control (MAP4K4). The CNOT6 siRNAs reduced CNOT6 mRNA expression 
over 80% in these cells (Fig. 4.2, p<0.0001). I chose HTT and SECISBP2L (SECIS 
Binding Protein 2 Like) as candidate CNOT6 targets. HTT and SECISBP2L shift to longer 
3′UTR isoforms in HD cerebellum and shorter isoforms in HD motor cortex. I collected 
RNA from transfected cells for qPCR analysis of the HTT long 3′UTR isoform versus 
total HTT, and of the SECISBP2L long 3′UTR isoform versus total SECISBP2L. I found 
knock down of CNOT6 resulted in a decrease in the HTT and SECISBP2L long isoforms 
similar to that seen in HD patient motor cortex and in HD fibroblasts (Fig. 4.3A, p=0.03, 
0.001). HTT isoform-specific qPCR found that, as in HD patient motor cortex, the 
abundance of the short isoform didn’t change while abundance of the long isoform 
decreased by almost two-fold (Fig.4.3B, p=0.03). These results suggest changes in the 
expression of CNOT6 may influence the abundance of some 3′UTR isoforms in patient 
motor cortex and cerebellum. 
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Figure 4.2. CNOT6 siRNAs reduce CNOT6 but not HTT mRNA expression in wild-type 
fibroblasts. (A) qRT-PCR quantification CNOT6 mRNA compared to GAPDH mRNA 
after transfection of CNOT6 siRNA (gray), no siRNA (white), or non-targeting (NT) 
MAP4K4 control siRNA (black) into wild-type fibroblasts. *, **, and *** signify p<0.05, 
0.005, and 0.0005. (B) qRT-PCR quantification HTT (HTT) mRNA compared to 
GAPDH mRNA after transfection of CNOT6 siRNA (gray), no siRNA (white), or non-
targeting (NT) MAP4K4 control siRNA (black) into wild-type fibroblasts. 
 
 
 
 
 
 
 
 
 
 
 108 
 
Figure 4.3. Changes in the expression of CNOT6 influence isoform abundances. (A) 
qRT-PCR quantification of the HTT long isoform (long) compared to total HTT 
expression (total) or of the SECISBP2L long isoform (long) compared to total 
SECISBP2L expression (total) after transfection of CNOT6 siRNA (gray) or non-
targeting (NT) MAP4K4 control siRNA (black) into wild-type fibroblasts. Shown is the 
average of at least three transfections with standard deviation. Red and blue bars are 
untreated fibroblasts, as in Fig. 1D. *, **, and *** signify p<0.05, 0.005, and 0.0005. (B) 
Isoform-specific qRT-PCR quantification of each HTT long isoform (long) compared to 
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total HTT expression after transfection of CNOT6 siRNA (colored), no siRNA (white), or 
non-targeting (NT) MAP4K4 control siRNA (black) into wild-type fibroblasts. 
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4.3 Discussion 
I sought to determine a possible mechanism for widespread 3′UTR isoform 
changes in disease. I found knockdown of CNOT6, an RNA binding protein involved in 
mRNA metabolism differentially expressed in HD brain, produced HTT mRNA isoform 
alterations similar to those seen in HD motor cortex. My results point to a model in which 
changes in the expression of RNA binding proteins in the HD brain lead to changes in the 
expression of mRNA 3′UTR isoforms (Fig. 4.4). RNA binding proteins may interact with 
nascent mRNA during transcription and alternative polyadenylation, leading to changes 
in polyA site selection and isoform production. For instance, aberrant expression of 3′ 
end modulatory factors known to correlate to polyA site selection may lead to isoform 
abundance changes
45
. I found three 3′ end processing factors are differentially expressed 
in HD grade 1 motor cortex: CPSF2, PCBP2, and THOC5. In addition to interacting with 
transcripts during alternative polyadenylation, RNA binding proteins may adhere to 
isoforms post-transcriptionally, affecting the stability and decay of isoforms and leading 
to changes in isoform abundance. I show a decrease in the CNOT6 deadenylase is 
associated with a decrease in the HTT long isoform, indicating the long isoform is more 
sensitive to changes in CNOT6 expression, perhaps due to its short poly-A tail.  
Further studies are necessary to determine the mechanism of 3′UTR isoform 
changes in HD. I found HTT and SECISBP2L isoform amounts are responsive to changes 
in CNOT6 mRNA levels. However, I only tested two mRNAs for response to CNOT6 
levels. Altered CNOT6 expression may not explain all isoform changes I identified. Other 
RNA binding proteins, such as 3′ end processing factors in Fig. 4.1, likely affect isoform 
 111 
abundance in HD. Exploration of the causes of isoform changes in HD motor cortex may 
result in novel therapeutic targets. 
 
 
Figure 4.4. Changes in the expression of RNA binding proteins may influence 
alterations in isoform abundances in HD. Model of mRNA 3′UTR isoform changes in 
HD. Changes in the expression of RNA binding proteins lead to changes in mRNA 
3′UTR isoform (red, green) abundance either by altering the production of some isoforms 
during transcription and alternative polyadenylation, or by affecting the stability of some 
isoforms post-transcriptionally. Widespread changes in isoform abundance likely lead to 
changes in stability, localization, and translation via different interactions with RNA 
binding proteins (dark blue) or microRNAs (orange), or differences in polyA tail length. 
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4.4 Materials and methods 
4.4.1 CNOT6 siRNA transfection. I transfected wild-type fibroblasts with three CNOT6 
siRNAs (Qiagen FlexiTube) using Lipofectamine RNAimax transfection reagent 
(Invitrogen) per manufacturer’s instructions. After 72 hours, RNA was collected, 
DNAsed, reverse transcribed, and submitted to quantitive RT-PCR.  
 
4.4.2 Quantitative RT-PCR. Total RNA was extracted using Trizol (Ambion), and RNA 
quality was assessed by Bioanalyzer (Agilent). RNA was treated with TurboDNAse 
(Ambion), and cDNA was synthesized from 2μg total RNA using SuperScript IV 
(Invitrogen) with oligo d(T)20 priming per manufacturer’s instructions. Quantitative PCR 
was performed with 1.8μl cDNA, 1μM forward and reverse primers, and QuantiFast 
SYBR green master mix (Qiagen). Reactions were incubated at 95°C for 5 minutes, 
followed by 40 cycles of 95°C for 10 seconds and 60°C for 30 seconds. on a StepOnePlus 
Real-Time PCR System (Thermo Fisher Scientific). The CAMKK2, GJA1, and GFAP 
PrimePCR Assay primer mixes (Biorad) were used at 1x in the PCR reaction. All primers 
were validated by relative standard curve, and primer pairs amplified targets with 85-
115% efficiency in the linear range. I verified primer specificity by running qPCR 
products on a 2% agarose, 1x TAE gel, extracting the bands using the QIAquick Gel 
Extraction Kit (Qiagen), and Sangar sequencing the bands with the forward and reverse 
PCR primers.  
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Table 4.1 Primers used in chapter 4 (AS=allele-specific, NAS=non allele-specific, IS=isoform specific 
Primers (5′-3′)   
Target Forward Reverse 
HTT long 3′UTR  ATGGATGCATGCCCTAAGAG CAGTCTCCGATGAGCACAGA 
total HTT CATGGTGGGAGAGACTGTGA CAAAGAGCACTTCTGCCACA 
SECISBP2L long 
3′UTR  
TGAAGGGATTTTCATCTTTTGCT
GT 
AGTACAGAAGAATCCCCACTAG
TAT 
total SECISBP2L CCCTCATCCCTTCCAACCTTT ACTTTCAAGGTGTGATGTGCCA 
CNOT6 ACAGAGTGCCTATGAGAGTGGC CAGGATGCCTAAGGTGTTCAGC 
GAPDH GAGTCAACGGATTTGGTCGT TTGATTTTGGAGGGATCTCG 
(IS) HTT long 3′UTR  GGAAGGACTGACGAGAGATG ACGCATCTATGCGCATATCG 
(IS) HTT short 3′UTR  
(IS) HTT mid 3′UTR  
AGCAGGCTTTGGGAACACTG 
GTGGCAAGCACCCATCGTAT 
 
ACGCATCTATGCGCATATCG 
ACGCATCTATGCGCATATCG 
 
Reverse transcription primers (5′-3′)  
Isoform-specific ACGCATCTATGCGCATATCGTTTTTTTTTTTTTTT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 114 
CHAPTER V: CONCLUSIONS 
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I show alternatively polyadenylated isoforms of full-length HTT mRNA, 
including a novel mid-3′UTR isoform, change their steady-state abundance in HD cells 
and tissues. Isoform changes are tissue-specific and arise from both HTT alleles. HTT 
isoform changes in HD likely impact total HTT mRNA metabolism: HTT isoforms have 
different localizations, stabilities, polyA tail lengths, microRNA sites, and RNA binding 
protein sites. Isoform changes extend beyond HTT. Eleven percent of mRNAs exhibit 
altered 3′UTR isoform abundance in HD motor cortex. Most genes with isoform changes 
are not differently expressed, but they are enriched in pathways involved in HD 
pathogenesis. These results suggest isoform changes may contribute to HD pathogenesis 
independently of gene expression changes. Altered expression of RNA binding proteins 
may affect isoform abundance in HD.  I found knockdown of the multifunctional RNA 
binding protein CNOT6 results in altered isoform abundances in cells. This is the first 
study to characterize HTT 3′UTR isoform metabolism and show extensive 3′UTR 
changes are a feature of HD. 
Isoform alterations are not surprising, given DNA and RNA expression and 
processing are deregulated in HD
41,123
. Further studies are necessary to elucidate the role 
of 3′UTR isoform changes in HD. Several questions require further investigation. The 
mechanism of isoform changes remains to be established, and it is unclear if or how 
changes in isoform expression cause pathology. The etiology of HD is multifactorial, and 
it is likely some molecular and cellular changes are causes, some are results, and some 
are epiphenomenon of pathology. Here, I discuss these unresolved questions and the 
directions future research could take to answer them. 
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5.1 Isoform changes may be due to differential expression of RNA binding proteins 
in HD. 
I hypothesized isoform changes are due to differential expression of RNA binding 
proteins in HD.  Isoform changes may arise due to altered synthesis of 3′UTR isoforms 
during alternative polyadenylation, or due to altered decay of 3′UTR isoforms after 
mRNA processing. I expect differential expression of RNA binding proteins involved in 
mRNA 3′ processing will affect isoform production, whereas differential expression of 
proteins involved in mRNA stability will affect decay. Changes in 3′UTR isoform 
synthesis or decay could alter isoform steady state abundance. 
 Knockdown of the deadenylase CNOT6, a subunit of the multifunctional Ccr4-
Not complex that regulates mRNA metabolism, alters the expression of HTT and 
SECISBP2L 3′UTR isoforms. CNOT6 is more differentially expressed in HD motor 
cortex than in HD cerebellum, which is consistent with greater isoform changes in motor 
cortex than in cerebellum (Fig. 4.1). CNOT6 and the Ccr4-Not complex impact the 
stability and deadenylation of specific mRNAs
214
. Differential expression of CNOT6 in 
HD could result in widespread changes in stability, polyA tail length, or both. Global 
trends in mRNA polyA tail lengths can be determined by polyA tail sequencing (PAT-
seq) with or without CNOT6 knockdown in control fibroblasts
101
. If differential CNOT6 
expression in HD impacts global polyA tail lengths, I would expect a transcriptome-wide 
shift in polyA tail length after CNOT6 knockdown.  If polyA tail length changes occur, 
they may be a cause of isoform abundance alterations, as a transcript’s polyA tail length 
can impact its stability
101,102
. CNOT6 may also modulate isoform stability independently 
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of deadenylation, and changes in polyA tail length maybe an epiphenomena to isoform 
abundance alterations. 
The mRNA of several proteins involved in mRNA 3′ processing is differentially 
expressed in HD brains including Cleavage and Polyadenylation Specificity Factor 2 
(CPSF2), Poly(C) Binding Protein 2 (PCBP2), and THO Complex Subunit 5 Homolog 
(THOC5). CPSF2 recognizes and binds the polyA signal during cleavage and 
polyadenylation
45
. PCBP2 binds poly-cytosine regions near polyA signals in the 3′UTR 
and enhances cleavage and polyadenylation
216
. THOC5 recruits cleavage factor 1 (CF1) 
to nascent mRNAs, promoting cleavage and polyadenylation
217
. Aberrant expression of 
these 3′ processing proteins in HD may affect synthesis of 3′UTR isoforms to impact 
steady-state 3′UTR isoform abundance. However, altered expression of 3′ processing 
proteins generally leads to global shifts in 3′UTR length to predominately shorter or 
longer isoforms, which I did not observe in my data
45
. 
The impact of each of these RNA binding proteins on 3′UTR isoform abundance 
can be tested in vitro. Each protein can be knocked down in control fibroblasts, and then 
PAS-seq can be performed on the fibroblasts’ mRNA. If isoform changes occur in control 
fibroblasts, RNA binding protein expression can then be supplemented to determine if 
they rescue isoform changes.  Isoform changes may also be due to aberrant RNA binding 
protein activity rather than expression. Many proteins are sequestered into HTT 
aggregates in HD
198
. Sequestration of proteins involved in isoform synthesis or decay 
into aggregates may alter or ablate their function. Here, I only measured differential 
expression of RNA binding proteins, not altered activity. To identify RNA binding 
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proteins that may be sequestered by mutant HTT, mutant HTT could be 
immunoprecipitated from HD fibroblasts followed by mass spectrometry or co-
immunoprecipitation for RNA binding proteins. Knockdown of these RNA binding 
proteins then be performed as described followed by HTT isoform-specific qPCR or 
PAS-seq. If sequestration of RNA binding proteins into aggregates impairs their function, 
I would expect knockdown of the RNA binding proteins in control fibroblasts would 
result in isoform changes similar to those in HD fibroblasts. 
RNA binding proteins may interact directly or indirectly with target transcripts to 
impact isoform abundance. To identify proteins that directly interact with HTT and other 
mRNAs with isoform changes, the candidate RNA binding protein could be 
immunoprecipitated and attached mRNAs could be submitted to PAS-seq. Alternatively, 
HTT transcripts could be pulled down and attached proteins submitted to mass 
spectrometry. In addition, genes with isoform changes in HD motor cortex could be 
queried for common motifs that may be sites for RNA binding proteins. 
 These experiments will help determine RNA binding proteins that may be 
responsible for isoform changes in HD. If the causative RNA binding proteins are 
involved in mRNA stability, I expect isoform alterations arise at steady-state; if the 
causative RNA binding proteins are involved in mRNA 3′ processing, I expect changes 
arise during alternative polyadenylation. Whether isoform changes arise during or after 
transcription and alternative polyadenylation can be assessed by ethinyl-uridine pulse 
chase in cell models. HD fibroblasts exhibit changes in HTT isoform expression 
compared to controls and may exhibit transcriptome-wide changes. HD or control 
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fibroblasts can be pulsed with ethinyl-uridine for one hour, during which HTT mRNA is 
transcribed but does not decay, or twelve hours, after which isoform abundances reach 
steady-state levels (see Figure 2.10B). Cells can then be washed, and labeled mRNA can 
be collected and HTT isoform-specific qPCR or PAS-seq performed. If isoform changes 
arise during alternative polyadenylation, they will be evident after one-hour incubation 
with modified uridine. If they arise only at steady state, they will only be present after the 
twelve-hour incubation.  
 If isoform changes contribute to HD pathogenesis, RNA binding proteins or other 
factors involved could be novel therapeutic targets. In addition, if HTT isoforms 
differentially impact HD pathogenesis, specific HTT isoforms may be effective targets of 
HTT-lowering therapies. 
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5.2 HTT 3′UTR isoform changes may contribute to HD pathogenesis. 
The relative increase in the HTT short isoform in HD patient motor cortex may 
contribute to pathogenesis. During preparation of this dissertation, a study was published 
by Xu, An, and Xu exploring the impact of HTT 3′UTR length on cellular HD 
pathogenesis
39
. Researchers created constructs expressing mutant HTT exon 1 or full-
length GFP followed by the short or long HTT 3′UTR. They found transfection of the 
long HTT 3′UTR directed GFP expression to the dendrites of cultured rat neurons, 
whereas transfection of the short 3′UTR restricted expression to the soma.  HTT exon 1 
constructs with the short 3′UTR produced more aggregates in cells, likely due to 
increased translational efficiency of the short 3′UTR construct compared to the long 
construct. This is consistent with my finding that the short HTT 3′UTR isoform has 
increased stability and polyA tail length compared to the long isoform, both of which are 
correlated to translation efficiency
102
. Given these findings, I would expect that the 
relative increase in the HTT short 3′UTR isoform in HD motor cortex results in increased 
HTT aggregates compared to the cerebellum, where there is a decrease in the HTT short 
3′UTR isoform.  
Further experiments are necessary to determine if HTT 3′UTR isoforms have 
different pathogenicity. The Xu study used artificial, overexpressed isoform constructs 
out of the normal HTT genomic context in embryonic cultured neurons. The constructs 
did not express full-length HTT cDNA, but only HTT exon 1, or the GFP open reading 
frame, followed by the short or long HTT 3′UTR. These constructs are not spliced or 
transcribed normally and likely have different secondary structure and associated 
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proteins, which may impact isoform stability, localization, and translation. Studies on 
endogenous HTT mRNA are ideal to assess isoform pathogenicity. HD or control patient 
induced pluripotent stem cells with varying CAG numbers could be differentiated into 
medium spiny neurons
218
. Prior to differentiation, CRISPR/Cas9 technology could be 
applied to mutate the polyA sites of the short, mid, or long isoform, and clonal 
populations could be generated that express only one HTT 3′UTR isoform. HD medium 
spiny neurons expressing the short, mid, and long HTT 3′UTR isoform could be 
compared. Ribosome profiling could be used to compare isoform translation rates, 
ethinyl-uridine pulse chase could be used to confirm isoform stabilities, and RNA 
fluorescent in-situ hybridization (FISH) could be used to compare isoform localization. 
To test isoform pathogenicity, cell stresses or BDNF withdrawal could be applied to HD 
medium spiny neurons expressing each HTT isoform, and cell toxicity could be compared 
to controls
218
. These experiments will compare the metabolism and pathogenicity of each 
endogenous HTT 3′UTR isoform, and will test the hypothesis that the short HTT 3′UTR 
isoform is more pathogenic in neuronal cells. 
There is variation in HTT 3′UTR isoform abundance across patient brain samples 
(see Fig. 2.8). I found isoform abundance is not correlated to CAG repeat number (p>0.5 
for all isoforms). If HTT 3′UTR isoforms have different pathogenicity, variations in 
isoform abundance may contribute to variable age of onset in patients with the same 
CAG repeat number. I do not know the age of onset for my patient samples. Once the 
pathogenicity of isoforms has been determined, the contribution of isoform abundance to 
age of onset can be determined. The abundance of each HTT isoform in multiple patients 
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with similar CAG repeat numbers could be determined by PAS-seq, and the power of 
isoform abundance to predict age of onset could be determined by regression analysis. 
If the short HTT isoform is more pathogenic, it will be an effective target for HD 
RNA and DNA therapies. The polyA site of the short isoform could be mutated using 
CRISPR/Cas9, leading to decreased production of the pathogenic isoform without 
inactivating the gene entirely, which could be potentially deleterious given its pro-
survival functions. Targeting the HTT short isoform mRNA would be more challenging, 
as it shares its entire sequence with the mid and long isoforms. Interfering RNAs or 
antisense oligonucleotides could be designed to target the interface between the isoform 
and the polyA tail. In contrast, if the long isoform is more pathogenic, therapies could 
target sequences unique to the long 3′UTR. Isoform-specific therapies may enhance 
targeting of pathogenic HTT mRNA transcripts while sparing protective transcripts. 
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5.3 Changes in the abundance of 3′UTR isoforms of other genes may contribute to 
HD pathogenesis. 
Genes with 3′UTR isoform changes in HD patient brains are implicated in disease 
pathogenesis. Two proteins that modulate mutant HTT aggregation are among the top 
five genes with isoform changes in motor cortex from grade 1 HD brains: WD repeat and 
FYVE domain-containing protein 3 (WDFY3), and WW Domain Containing E3 
Ubiquitin Protein Ligase 1 (WWP1). WDFY3, which exhibits the greatest shift towards 
longer mRNA 3′UTR isoforms, is involved in autophagy of ubiquitinated bodies and 
promotes turnover of mutant HTT protein
219,220
. In contrast, WWP1, which exhibits the 
third greatest shift towards shorter isoforms, ubiquitinates mutant HTT to prevent its 
turnover and promote aggregate formation
221
. WDFY3 and WWP1 are likely involved in 
neuropathology, as HTT aggregation is thought to play a central role in HD 
pathogenesis
27
.  Mutations in another gene that shifts to shorter isoforms in HD motor 
cortex, pantothenate kinase 2 (PANK2), are associated with Hallervorden-Spatz 
syndrome, an HD-like syndrome characterized by neurodegeneration and severe 
dystonia, suggesting changes in PANK2 expression might contribute to 
neurodegeneration in HD
222
. 
In the cerebellum, Collagen Type XVI Alpha 1 Chain (COL16A1) exhibits the 
second greatest shift to longer 3′UTR isoforms. COL16A1 encodes a collagen protein that 
maintains integrity of the extracellular matrix. In neurons null for the HTT gene, 
COL16A1 and other extracellular matrix proteins are most down-regulated, suggesting 
wild-type HTT promotes their expression
223
. The Sodium Voltage-Gated Channel Alpha 
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Subunit 3 (SCN3A) shifts to shorter 3′UTR isoforms in HD cerebellum. Decreased 
expression of the beta subunits of these voltage-gated sodium channels contributes to 
excitotoxicity in HD
224
. Ubiquitin-conjugating enzyme E2 J1 (UBE2J1), which shifts 
towards shorter isoforms in HD, catalyzes attachment of ubiquitin to proteins. UBE2J1 is 
a target of REST and CoREST, transcriptional repressors with increased activity in 
HD
140,225
.  
In motor cortex from grade 2 HD brains, there are three outlier genes with 
extreme isoform shifts: Nedd4 Family Interacting Protein 1 (NDFIP1), Adaptor Related 
Protein Complex Gamma 1 Subunit (AP1G1), and Cathepsin B (CTSB). NDFIP1 protein 
plays a vital role in healing cortical injury, wheras AP1G1 is essential for formation of 
clathrin-coated vesicles
202,203
. Wild-type HTT interacts with other proteins to regulate 
clathrin-mediated endocytosis; this process is disrupted in HD
28,226
. CTSB protein was 
recently found to mediate the beneficial effect of exercising on hippocampal 
neurogenesis, an effect that is lost in mouse models of HD, suggesting CTSB is impaired 
in disease
205,206
.  
Other genes with large isoform shifts in HD patient brains have not been 
implicated in pathogenesis, but they may still play a role in disease. In motor cortex, 
Ubiquitin Specific Peptidase 53 (USP53), Nuclear Cap Binding Subunit 3 (NCBP3), 
Echinoderm Microtubule Associated Protein Like 1 (EML1), NADH:Ubiquinone 
Oxidoreductase Subunit A2 (NDUFA2), Solute Carrier Family 22 Member 23 
(SLC22A23), and Neurolysin (NLN) shift to longer or shorter 3′UTR isoforms in HD.  
These genes are involved in cytokine signaling (USP53), mRNA nuclear export 
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(NCBP3), assembly of microtubules (EML1), mitochondrial metabolism (NDUFA2), 
anion transport (SLC22A23), and oligopeptide hydrolysis (NLN). Several of these 
pathways, including cytokine signaling, mitochondrial metabolism, and ion transport, are 
involved in HD pathogenesis
27
. Genes with isoform changes are also enriched for gene 
ontology pathways involved in HD pathogenesis such as calcium signaling, cytokine 
signaling, histone acetylation, transcription factor binding, axonal transport, synaptic 
vesicle localization, dendritic spine morphogenesis, microtubule organizing, and 
phagocytic vesicles
197–201
.  
Changes in the steady-state abundance of these 3′UTR isoforms of may contribute 
to HD pathogenesis. The impact of 3′UTR length on these mRNAs is unknown, and the 
fold change in isoform expression required for biological changes has not been 
established. However, as these genes are involved in HD pathogenesis, 3′UTR isoform 
changes may contribute to altered protein function and toxicity. For instance, WWP1 and 
WDFY3 modulate HTT protein turnover. If different mRNA 3′UTR isoforms of these 
proteins are localized differently or have different stability, isoform changes may affect 
the amount and localization of the resulting proteins. Altered expression or localization of 
WWP1 and WDFY3 may result in decreased turnover of HTT aggregates and increased 
pathology. Alternatively, isoform changes may be protective, resulting in increased 
turnover of HTT. In either scenario, isoform changes may impact HD pathogenesis. 
Further studies are necessary to determine if isoform changes in HD change the 
metabolism and translation of mRNAs such as WWP1 and WDFY3. 
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Cell models can be used to determine the effect of isoform changes on total 
mRNA metabolism. HD fibroblasts exhibit HTT 3′UTR isoform changes, and may also 
exhibit transcriptome-wide changes like HD patient brains. HD and control fibroblast 
mRNA can be submitted to PAS-seq to determine if HD fibroblasts exhibit widespread 
isoform changes compared to controls.  HD mouse model primary neurons or striatal cell 
lines can also be tested. In addition, patient or control fibroblasts differentiated into 
neural stem cells could be tested
218
. All of these disease cells display a phenotype, 
although the fibroblast phenotype is subtle
218,227,228
. 
Once a cell model is identified, mRNA metabolism can be assayed in disease and 
control cells. Global mRNA stability can be measured via ethinyl uridine pulse chase 
followed by PAS-seq. Transcript localization can be tested using polyA tail FISH. 
Isoform translation rates can be determined with ribosome profiling. These experiments 
will measure differential metabolism of mRNA isoforms of the same gene in normal 
cells, and identify alterations in mRNA metabolism in disease cells. Because 3′UTR 
length impacts mRNA localization, stability, and translation, I expect genes with isoform 
changes will also exhibit changes in metabolism of their mRNAs
132
. Altered mRNA 
metabolism may impact the abundance and localization of proteins involved in HD 
pathogenesis, potentially contributing to neurotoxicity. 
Once the mechanism of isoform alterations is identified, the impact of isoform 
changes on HD pathogenesis can be determined. For instance, if decreased CNOT6 levels 
affect global isoform abundance in HD, CNOT6 can be exogenously supplied in control 
cells to normalize protein levels. PAS-seq can be performed to confirm exogenous 
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CNOT6 rescues some or all isoform changes. Cells could then be assayed for HD 
phenotypes to determine if normalization of isoform abundances had any impact on 
disease pathology. Results would have to be interpreted with care, since CNOT6 or other 
RNA binding proteins may reduce HD pathogenesis independently of isoform 
abundances, even if exogenous expression shifts isoform amounts towards normal. 
If 3′UTR isoform changes contribute to HD pathogenesis, RNA binding proteins 
that impact 3′UTR isoform expression may be novel therapeutic targets. The ideal HD 
therapy will correct the mutant HTT gene or mRNA. However, it is difficult to target 
mutant HTT without targeting the neuroprotective wild-type HTT. In addition, gene and 
RNA therapies using short oligonucleotides have many off-target effects
229
. Down-
regulated RNA binding proteins could be rescued by exogenous protein expression. As 
there are few treatments for HD, any novel therapeutic targets may be beneficial to 
patients. 
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5.4 Conclusions: Treating HD. 
In conclusion, in this dissertation I detail a novel feature of HD pathology: 
changes in the abundance of mRNA 3′UTR isoforms, including HTT. The mechanism 
and effect of these changes remains to be established. HD pathogenesis is multifactorial. 
Isoform changes may be causes or consequences of HD pathology. However, expression 
of the mutant HTT mRNA and protein is central to all pathology in HD, and HTT-
lowering treatments may alter the course of HD and improve the lives of patients. This 
dissertation characterizes the abundance, stability, and localization of the predominant 
HTT mRNA isoforms in normal and disease cells. These findings deepen our 
understanding of HD, and will aid the design of therapeutics.  
Many putative treatments aim to reduce expression of HTT mRNA or DNA 
before it can cause toxicity
229
. Antisense oligonucleotides, small interfering RNAs 
(siRNAs), and artificial microRNAs have been designed to lower HTT mRNA levels in 
pre-clinical studies
229
. Antisense oligonucleotides are single-stranded DNA molecules 
that anneal to HTT mRNA. The RNA-DNA duplex is cleaved by RNAse H. siRNAs are 
double-stranded RNAs. The strand complementary to the HTT mRNA is loaded into the 
RNA induced silencing complex (RISC), which cleaves target HTT mRNA. Artificial 
microRNAs are designed with backbones and structure identical to an endogenous 
microRNA, but the region that gets loaded into RISC anneals to HTT mRNA, resulting in 
cleavage or translation suppression. Enzymes that cut DNA including Zinc finger 
nucleases and Clustered Regularly Interspaced Short Palindromic Repeats 
(CRISPR/Cas9) have been used to therapeutically target the HTT gene
230,231
. All of these 
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therapies have to be modified or packaged into viruses or lipid vesicles for delivery to the 
brain
229
. Delivery is difficult, as direct injection in the brain via neurosurgery is invasive 
and could potentially cause infection, whereas intrathecal delivery saturates the brain 
surface while missing deeper structures such as the striatum, and peripheral delivery is 
largely cleared by the liver and may not cross the blood brain barrier
229
. 
An additional challenge of all HTT-lowering strategies is allele specificity. Wild-
type HTT performs many important functions in cells, and reduction below 50% of 
normal levels is deleterious
26
. The ideal HD therapy would target mutant but not wild-
type HTT. However, mutant and wild-type HTT DNA and mRNA are identical except for 
the CAG repeat length and heterozygous SNPs.  Putative HTT therapies aim to target the 
CAG expansion, or SNPs in the mutant but not wild-type allele
46,47,232,233
.  
As described, if one mutant HTT 3′UTR isoform is more pathogenic, it could be 
targeted at the DNA or RNA level, whereas if one isoform is protective, it could be 
supplemented. I show HTT 3′UTR isoforms have different localizations. HTT mRNA-
lowering therapies could be directed to cellular compartments enriched for HTT isoforms. 
The region unique to the long mRNA isoform the ideal target for RNA-lowering 
therapies, as I show there is a decrease in the long HTT 3′UTR isoform in patient motor 
cortex. Thus, my findings will aid in design of therapies targeting HTT mRNA and DNA.   
HD is a complicated disease with changes in many cellular processes: epigenetics, 
transcription, splicing, translation, metabolism, signaling, vesicle transport, and 
survival
198
. Here, I describe another cell process deregulated in HD: 3′UTR isoform 
abundance. How isoform changes fit into the complex landscape of HD pathogenesis 
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remains to be established. However, HTT mRNA and protein are at the core of all 
changes in HD. Many HTT-lowering therapies are nearing clinical trials. As there is 
currently no disease-altering treatment for HD, these therapies hold great promise for the 
families devastated by HD. The findings described in this dissertation reveal a new aspect 
of HD pathology and provide some recommendations for HD therapy. It is my hope that 
soon there will be a disease-altering treatment for this terrible disease. 
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APPENDIX I: LINKING SNPs TO THE CAG REPEAT EXTENDED RANGE 
(“SLIC-er”) 
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Preface 
 This work was a collaborative effort. Jonathon Watts designed the modified 
oligonucleotides. Rachael Miller and I performed the screens.  
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A.1 Summary 
 Mutant HTT protein causes pathology at the DNA, RNA, and protein level and 
disrupts the function of wild-type HTT. Wild-type HTT protein interacts with several 
other proteins to play a role in neuronal survival, synaptic activity, and vesicle transport. 
Putative HD therapies aim to decrease HTT mRNA before it is translated into the 
pathogenic protein
229
. However, it may be detrimental to decrease mRNA levels from 
both HTT alleles, given the important functions of wild-type HTT. Thus, several 
therapeutic approaches aim to target mutant but not wild-type HTT mRNA.  
 Antisense oligonucleotides, small interfering RNAs (siRNAs), and artificial 
microRNAs can lower HTT mRNA levels in vitro and in vivo
229
. Making these therapies 
allele-specific is challenging. The mutant and wild-type HTT mRNAs are nearly identical 
except for the CAG repeat expansion; designing antisense oligos or siRNAs targeting the 
CAG repeat is virtually impossible given the short length of these therapeutics. One 
strategy for allele-specific silencing is via microRNA-like RNA duplexes targeting the 
CAG repeat, which more effectively silence a target when more duplexes are bound. 
Since there are more CAG repeats on the mutant allele, these duplexes cause more 
silencing of the mutant than wild-type allele
233
. However, there is still substantial 
silencing of the wild-type allele using this method. Another strategy targets siRNAs to 
the Δ2642 deletion in HTT exon 58, which is linked to the mutant allele232. This treatment 
will only work on the subset of patients that have this mutation on the mutant but not 
wild-type allele. A third strategy for allele-specific silencing is targeting frequently-
heterozygous SNPs in HTT with siRNAs or antisense oligonucleotides, which can be 
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engineered to effectively silence the mutant but not wild-type allele in vitro
46,47
. To be 
effective, these therapies require knowledge of which SNP corresponds to the mutant 
allele.  
 Our lab has published a method for SNP-linkage to the CAG repeat in HD 
patients (SLiC)
234
.  In the method, HTT mRNA is reverse transcribed, and a PCR is 
performed from exon 1 to the SNP using primers with restriction enzyme sites. The PCR 
products are cleave with restriction enzymes and then ligated into circular cDNA. An 
inverse PCR is then performed spanning the SNP and exon 1, and the products are 
sequenced to determine the linkage of the SNP to the CAG repeat
234
. This method is 
effective for SNPs proximal to exon1; however its efficacy drops for more distal SNPs 
due to decreased efficiency of the long-range PCR. The ideal SNP-linkage method would 
be effective regardless of the SNP position, as several frequently heterozygous SNPs are 
located in the HTT 3′UTR, up to 12kb away from exon 146. 
 I developed a method for SNP-linkage to the CAG repeat at extended ranges, 
SLiC-er (Fig. A.1). Total RNA is treated with RNAsH and a SNP-specific DNA 
oligonucleotide, resulting in cleavage of one allele but not the other. HTT mRNA is 
reverse transcribed with an oligo d(T) primer, and exon 1 PCR is performed on full-
length cDNA and resolved via agaorse gel electrophoresis. Little full-length mRNA is 
transcribed from the allele matching the oligonucleotide, as most of it is cleaved during 
the RNAse H step.  Thus, the oligo-matching allele is faint or absent on the gel, enabling 
linkage of the SNP to the allele. 
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Figure A.1. Schematic of SNP-linkage to CAG-repeat extended range (SLIC-er) method. 
The DNA oligo is shown in purple; red represents the expanded CAG repeat; arrows represent 
primers. 
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A.2 Results 
We designed oligonucleotides complementary to the region surrounding five 
SNPs frequently heterozygous in HD patients: rs363099 in exon 29, rs362336 in 
exon 48, rs362331 in exon 50, rs362273 in exon 57, and rs362306 in the 3′UTR. For 
each SNP, we designed three unmodified DNA oligonucleotides with the nucleotide 
complementary to the SNP at or around the center position (Table A.1). Total RNA 
from Yac128 mice was DNAse treated and subjected to incubation with RNAse H 
and each candidate oligonucleotide or an off-target oligonucleotide. RNAse H 
degraded the RNA strand in the DNA-RNA hybrids. Treated RNA was then reverse 
transcribed from an oligo(dT) primer with conditions optimized to produce full-
length HTT cDNA (see methods). Transcripts reverse transcribed from mRNA 
cleaved by RNAse H terminate at the cleavage site and do not reach HTT exon 1. To 
assay the efficacy of RNAse H cleavage, the CAG repeat in exon 1 or a region distal to 
the SNP in the 3′UTR was PCR amplified. Products were resolved on a 2% agarose 
gel. There was reduced PCR product for all three oligonucleotides for each SNP 
compared to the off-target control and the distal 3′UTR (Fig. A.2). SNP rs362306A/G 
located in the HTT 3′UTR was most efficiently silenced. 
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Table A.1 Unmodified DNA oligonucleotides. 
rs363099 (T/C) Exon 29 
1 5′- CTGAGCGAAGAAACC -3′ 
2 5′- TGAGCGAAGAAACCC -3′ 
3 5′- GCTGAGCGAAGAAAC -3′ 
rs362336 (A/G) Exon 48 
1 5′- CCGCCGGTTCTGCAG -3′ 
2 5′- CGCCGGTTCTGCAGG -3′ 
3 5′- GCCGCCGGTTCTGCA -3′ 
rs362331 (C/T) Exon 50 
1 5′- CACAGTGGATGAGGG -3′ 
2 5′- ACAGTGGATGAGGGA -3′ 
3 5′- ACACAGTGGATGAGG -3′ 
rs362273 (G/A) Exon 57 
1 5′- TGATCTGCAGCAGCA -3′ 
2 5′- GATCTGCAGCAGCAG -3′ 
3 5′- TTGATCTGCAGCAGC -3′ 
rs362306 (A/G) 3’ UTR 
1 5′- GCAGCTGTAACCTGG -3′ 
2 5′- CAGCTGTAACCTGGC -3′ 
3 5′- AGCAGCTGTAACCTG -3′ 
  
Unmodified DNA oligonucleotides.  The SNP is shown in red. Oligonucleotides were 
designed to match the Yac but not Bac transgene. 
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Figure A.2. Screen of RNAse H cleavage of five frequently-heterozygous SNPs via 
unmodified DNA oligonucleotides. RNA was extracted from Yac128 mouse tissue, treated with 
RNAseH and a matching or off-target DNA oligonucleotide, and reverse transcribed. PCR of 
HTT exon 1  (top) or 3′UTR distal to the SNP (bottom) was performed on the cDNA. OT 
signifies off-target (oligonucleotide complementary to human beta-actin).  
 
We designed two sets of modified oligonucleotides to discriminate between 
alleles heterozygous at rs362306. Our designs were based on studies that found 
oligonucleotides with central DNA regions surrounded by modified RNA bases are 
best at discriminating between HTT alleles in cells47. The first set of modified 
oligonucleotides we designed contained a 4-base DNA gap flanked on each end with 
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2′-O-methyl RNA, with the SNP site in two different positions (Table A.2). The 
second set of modified oligonucleotides contained a 6-base DNA gap flanked on each 
end with 2′-O-methyl, with the SNP site in varying positions as well as an additional 
mismatch. Studies have shown adding an additional mismatch to siRNAs heightens 
alelle specificity46. To test allele discrimination by our oligonucleotides, we treated 
total RNA from Bac21 or Yac128 mice as described. The oligonucleotides were 
complementary to the Yac128 but mismatched to the Bac21 rs362306. We found all 
oligonucleotides discriminated between the Yac and Bac HTT alleles (Fig. A.3). 
Oligonucleotides similar to these could be used to link the SNP to the CAG repeat in 
patients prior to allele-specific therapy. 
 
Table A.2. Modified oligonucleotides targeting rs362306. 
1 5′- GCAGCTGTAACCUG-3′ 
2 5′- AGCUGTAACCUGGC-3′ 
3 5′- GCAGCAGTAACCUG-3′ 
4 5′- AGCUGTATCCUGGC-3′ 
5 5′- AGCUGTAAACUGGC-3′ 
6 5′- AGCUGTATCCUGGC-3′ 
  
Black, red, or green bases are unmodified DNA; blue are 2′-O-methyl RNA. Red 
indicates the SNP. Green bases are an additional mismatch. Oligonucleotides were 
designed to match the Yac but not Bac transgene. 
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Figure A.3. Screen of SNP rs362306 discrimination by modified oligonucleotides and 
RNAseH. (A)  RNA was extracted from Yac18 or Bac97 mouse tissue, treated with RNAseH and 
a modified oligonucleotide matching Yac but not Bac rs362306, and reverse transcribed. PCR of 
HTT exon67 was performed on the cDNA. (B) PCR of HTT exon 1 was performed on cDNA of 
RNA treated with modified oligonucleotide 5 or 6 (see table A.2). 
 
 
 
 
 
 
 
 
 
 
oligonucleo de:	
100	
500	
1	 2	 3	 4	 5	 6	
100	
500	 100	
500	
5	 6	
Yac18	Bac97	 Yac18	Bac97	
Yac18	
Bac97	
 141 
A.3 Discussion 
 Our improved method to link a heterozygous SNP to the CAG repeat allows 
robust linkage of SNPs as far as the 3′UTR. Several further studies are necessary to 
validate the method. We have shown allele discrimination by oligonucleotides on RNA 
from homozygous mice.  However, the method will be used clinically on heterozygous 
RNA from HD patients. The next step is to test the method on RNA from Yac/Bac mice, 
which are heterozygous for rs362306.  The allele-SNP linkage is known for these 
mice, making them ideal for SLIC-er validation. Once the method is working well on 
RNA from Yac/Bac mice, it must be tested on RNA from heterozygous patient cells. 
Efficacy should also be shown for other SNPs in addition to rs362306. Once this 
method is optimized and validated, it will be easier and more reliable than existing 
methods and can be used clinically to direct therapeutics to the mutant but not wild-
type allele.  
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A.4 Materials and methods 
A.4.1 RNAse H treatment. Total RNA was extracted from mouse tissues using Trizol 
(Ambion), and RNA was treated with TurboDNAse (Ambion). One microgram of RNA 
was heated at 95° for 2 minutes with 1µg of the complementary oligonucleotide 
(IDT) in 1x RNAseH buffer (NEB). The reaction was slowly cooled to room 
temperature, and 4 units of E. coli derived RNase H enzyme (NEB) and RNase OUT 
(Invitrogen) were added. The reaction was incubated at 37° for 4 hours, then 65° for 
20 minutes.  
 
A.4.2 Reverse transcription. Treated RNA was reverse transcribed from an 
oligo(dT) primer using SuperScript IV (Invitrogen) per manufacturer protocol with 
the following modifications: 2M betaine and 0.6M trehalose were added to optimize 
production of full-length HTT, and the reaction was incubated at 42° for 2.5 
hours235.  Reactions were cleaned on a DNA clean and concentrate column (Zymo). 
 
A.4.3 HTT exon 67 PCR. At least 20ng cDNA was PCR amplified by GoTaq Green 
Master Mix (Promega) with 2μM forward and reverse primers 5′-
GGAGCCTCTCCTGCTTCTTT-3′ and 5′-CACCTCAAGCACAGACTGGA-3′. The 
reaction was incubated at 94°C for 5 minutes; 30 cycles of 94°C for 30 seconds, 60°C for 
30 seconds, and 72°C for 30 seconds; and 72°C for 5 minutes. Products were resolved on 
a 2% agarose, 1x TAE gel. 
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A.4.4 HTT 3′UTR PCR. At least 20ng cDNA was PCR amplified by Phusion Master 
Mix (ThermoFisher Scientific) with 2μM forward and reverse primers 5′-
ATGGATGCATGCCCTAAGAG-3′ and 5′-CAGTCTCCGATGAGCACAGA-3′. The 
reaction was incubated for 35 cycles of 98°C for 30 seconds, 64°C for 20 seconds, and 
72°C for 20 seconds followed by 72°C for 5 minutes. Products were resolved on a 2% 
agarose, 1x TAE gel.   
 
A.4.5 HTT Exon 1 PCR. At least 100ng cDNA was PCR amplified by PrimeStar GXL 
polymerase (Clontech) with 1μM forward and reverse primers 5′-GCCTCCGGGGACT 
GCCGTGC-3′ and 5′-CGGCTGAGGCAGCAGCGGCT-3′. The reaction was incubated 
at 98°C for 1 minute; 30 cycles of 98°C for 10 seconds and 68°C for 30 seconds; and 
68°C for 10 minutes. Products were resolved on a 2% agarose, 1x TAE gel.  
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APPENDIX II: PAS-SEQ ANALYSIS CODE 
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#Purple text corresponds to instructions for input to Unix terminal 
#Red text corresponds to names of shell files or names of R/python files run within 
shells 
#Green text corresponds to commenting within shell or R/python files 
 
#first, gunzip and combine all fastq into one file called read1.fastq (cat *.fastq > 
read1.fastq) 
#then, run: bsub -q long -n 24 -W 8:00 -R "rusage[mem=120000]" -o output.log -e 
error.log ./index_reads.sh 
 
#index_reads.sh: 
#!/bin/bash 
python index_sort.py 
 
#files for index_reads.sh: 
#index_sort.py: 
 
#input fastq contains all R1 reads 
inputfq=open('read1.fastq') 
inputfq=inputfq.readlines() 
#define indices (samples) 
indices=['GTGAT','CATCG','AGCTA','GGAGC','ACTGT', 'ATCTG', 
 'CGGGA','TAGCC','TGACT','ACAAG','ATTCA','TCTAC'] 
#loop over reads and search for index, write line to output 
for index in indices: 
 outputfq=open(str(index)+'.fastq','w') 
 for row in range(1,len(inputfq),4): 
  if index in inputfq[row][0:5]: 
   outputfq.write(inputfq[row-1]) 
   outputfq.write(inputfq[row]) 
   outputfq.write(inputfq[row+1]) 
   outputfq.write(inputfq[row+2]) 
 
#move all indexed files to their own folders, name by sample so ‘sample_index.fastq’ 
#in folders, run bsub -q long -n 24 -W 4:00 -R "rusage[mem=12000]" -o output.log -e 
error.log ../preprocess_shell.sh index 
 
#preprocess_shell.sh 
#!/bin/bash 
 
#need clean directory with this sh file, fastq file, bowtie pre-indexed hg19 genome for 
alignment (or symbolic link to the files), cleanUpdTSeq.R, cleanUpdTSeq.sh 
#input ($1)='filename' from filename.fastq 
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module load cutadapt/1.9 
module load openssl/1.0.1g 
 
#remove barcode+randomer and polyA from reads 
cutadapt -u 12 $1.fastq > noadapt.fastq 
cutadapt -a AAAAAAA noadapt > pAtrimmed.fastq 
 
#trim low quality bases, throw out reads <15nt after trimming 
cutadapt –q 25 –m 15 pAtrimmed.fastq > preprocessed.fastq 
 
#check quality of remaining reads 
module load fastqc/0.10.1 
fastqc preprocessed.fastq 
 
#run bsub -q long -n 24 -W 8:00 -R "rusage[mem=50000]" -o output.log -e error.log 
../PAS-Seq_all.sh 
sample_name 
 
#PAS-Seq_all.sh 
#!/bin/bash 
#align reads to genome, first download pre-indexed hg19 for bowtie (find online), need 
human UTR  
#coordinates from UCSC table browser in file named "hg19_3primeUTRcoordinates(+/-
).bed" with no 
#header and gene coordinates in “hg19genes(+/-).bed” with no header 
 
#$1 input is sample name 
module load bowtie/1.0.0 
bowtie -S hg19 preprocessed.fastq $1_aligned.sam 
 
#convert SAM to BAM 
module load samtools/0.0.19 
samtools view -S -b $1_aligned.sam > $1_aligned.bam 
 
#sort and index BAM file for viewing with IGV 
samtools sort $1_aligned.bam $1_aligned_sorted 
samtools index $1_aligned_sorted.bam $1_aligned_sorted.bai 
 
#convert BAM to BED file to identify peaks and falsely primed reads 
module load bedtools/2.25.0 
bamToBed -i $1_aligned_sorted.bam > $1_aligned_sorted.bed 
 
#compute read 3′ end NT coverage for + and – strand reads 
module load ucsc_cmdline_util/12_16_2013 
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fetchChromSizes hg19 > hg19.chrom.sizes 
genomeCoverageBed -strand + -bg -3 -i $1_aligned_sorted.bed -g hg19.chrom.sizes > 
$1_coverage+.bed 
genomeCoverageBed -strand - -bg -3 -i $1_aligned_sorted.bed -g hg19.chrom.sizes > 
$1_coverage-.bed 
 
#call and collapse reads onto peaks 
module load R/3.0.2 
Rscript ../peak_call_pw.R $1_coverage+.bed $1_peaks+.bed 
Rscript ../peak_call_pw.R $1_coverage-.bed $1_peaks-.bed 
 
#find gene names 3'UTR peaks are in 
intersectBed -a $1_peaks+.bed -b ../hg19_3primeUTRcoordinates+.bed -wa -wb > 
$1_UTRpeaks+.bed 
intersectBed -a $1_peaks-.bed -b ../hg19_3primeUTRcoordinates-.bed -wa -wb > 
$1_UTRpeaks-.bed 
 
#find gene names all peaks are in 
intersectBed -a $1_peaks+.bed -b ../hg19genes+.bed -wa -wb > $1_peaks_genes+.bed 
intersectBed -a $1_peaks-.bed -b ../hg19genes-.bed -wa -wb > $1_peaks_genes-.bed 
 
#files for PAS-Seq_all.sh 
#peak_call_pw.R 
 
#input 3′ end coverage file, define output filename 
args=commandArgs(T) 
input_coverage=args[1] 
output_peaks=args[2] 
 
peaks_all<-read.table(input_coverage) 
colnames(peaks_all)=c("chr","start","stop","coverage") 
 
#split reads by chromosome 
peaks_split = split(peaks_all, peaks_all$chr) 
all_data<-list() 
 
#loop over chromosomes to call peaks 
for (m in 1:length(peaks_split)) {  
 #make dataframe of reads from the chromosome, count number of reads in the 
dataframe 
peaks<-as.data.frame(peaks_split[m]) 
 colnames(peaks)=c("chr","start","stop","coverage") 
 n_reads<-nrow(peaks) 
#make the weights for a histogram with each peak position weighted by its 
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coverage 
  hist_weight<-rep(peaks[1,3],peaks[1,4]) 
 for (n in 2:nrow(peaks)) { 
  weighted1<-rep(peaks[n,3],peaks[n,4]) 
  hist_weight<-c(hist_weight,weighted1) 
 } 
 #make the histogram with bins 48 nucleotides wide 
range<-seq(from = (peaks[1,3]-48), to=(peaks[n_reads,3]+48), by=48) 
 histo_data<-hist(hist_weight,breaks=range) 
 bin_counts<-as.matrix(histo_data$counts) 
 breaks<-as.matrix(histo_data$breaks) 
 bins_breaks<-as.data.frame(cbind(breaks[1:nrow(breaks)-
1],breaks[2:nrow(breaks)],bin_counts)) 
 colnames(bins_breaks)=c("bin_start", "bin_end","count") 
 bins_breaks=bins_breaks[bins_breaks$count>4,] 
 nbins<-nrow(bins_breaks) 
#find maximum coordinate of peaks in bins with >4 reads; look upstream and 
downstream 24nt to offset histogram bins. Change coverage at that position to the 
sum of all surrounding area (24nt up and downstream) 
  window_peaks<-matrix(ncol=4) 
 colnames(window_peaks)=colnames(peaks) 
 for (k in 1:nrow(bins_breaks)){ 
  above<-peaks[peaks$stop>(bins_breaks[k,1]-24),] 
  window<-above[above$stop<=(bins_breaks[k,2]+24),] 
  max_position<-window[which.max(window[,4]),] 
  t<-peaks[peaks$stop>as.numeric((max_position[3]-24)),] 
  v<-t[t$stop<as.numeric((max_position[3]+24)),] 
  max_position[4]=sum(v[,4]) 
  window_peaks=rbind(window_peaks,max_position) 
 } 
 window_peaks=window_peaks[2:nrow(window_peaks),] 
 window_peaks=unique(window_peaks) 
 #remove any peaks that are on the border of bins 
 for (n in 1:(nrow(window_peaks)-1)) { 
  if (!is.na(window_peaks[n,3]) & !is.na(window_peaks[n+1,3])& 
as.numeric(window_peaks[n+1,3])-as.numeric(window_peaks[n,3])<25) { 
   mat<-rbind(window_peaks[n,],window_peaks[n+1,]) 
   index_remove<-which.min(mat[,4]) 
   index<-which(window_peaks[,3]==mat[index_remove,3]) 
   window_peaks[index,3]<-NA 
  } 
 } 
 window_peaks=na.omit(window_peaks) 
 all_data[[m]]=window_peaks 
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} 
 
all_cov=all_data[[1]] 
for (t in 2:length(all_data)){ 
 all_cov=rbind(all_cov,all_data[[t]]) 
} 
all_cov=all_cov[order(as.numeric(row.names(all_cov))),] 
 
write.table(all_cov, file=output_peaks, sep='\t', row.names=FALSE, col.names=FALSE, 
quote=FALSE) 
 
#clean up + and – strand 3′UTR and total gene peaks with cleanUpdTSeq to remove false 
polyA sites 
#run bsub -q long -n 24 -W 18:00 -R "rusage[mem=120000]" -o output.log -e error.log 
../cleanUpdTSeq.sh sample_name 
 
#cleanUpdTSeq.sh 
#!/bin/bash 
module load R/3.2.0 
Rscript ../cleanUpdTSeq.R $1_UTRpeaks+.bed $1_UTRpeaks-.bed 
$1_UTRpredictions.tsv $1_UTRpredictions.bed 
Rscript ../cleanUpdTSeq.R $1_peaks_genes+.bed $1_peaks_genes-.bed 
$1_all_predictions.tsv $1_all_predictions.bed 
 
#files for cleanUpdTSeq.sh 
#cleanUpdTSeq.R 
#takes 4 command line arguments: input+ peaks, input- peaks, outputfilename (tsv file of 
+ and – strand true peaks), outputfilename (bed file of + and - strand true peaks) 
 
#load required modules 
#source("http://bioconductor.org/biocLite.R") 
#biocLite("cleanUpdTSeq") 
library(cleanUpdTSeq) 
library(BSgenome.Hsapiens.UCSC.hg19) 
 
#read in data, convert to GRanges (peaks) 
args=commandArgs(T) 
input_plus_peaks=args[1] 
input_minus_peaks=args[2] 
output_filename=args[3] 
bed_peaks=args[4] 
 
testSet_plus <- read.table(input_plus_peaks, header=FALSE) 
testSet_plus = data.frame(testSet_plus[,1:4],testSet_plus[,8]) 
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colnames(testSet_plus)=c('chr','start','stop','score','geneID') 
testSet_minus <- read.table(input_minus_peaks, header=FALSE) 
testSet_minus = data.frame(testSet_minus[,1:4],testSet_minus[,8]) 
colnames(testSet_minus)=c('chr','start','stop','score','geneID') 
 
testSetall<-rbind(testSet_plus, testSet_minus) 
peak_names<-cbind(as.matrix(1:nrow(testSetall)),as.matrix(testSetall[,5])) 
 
#make testSet 6 columns with strand info in 6th column. column5=coverage 
strand_plus<-rep('+',nrow(testSet_plus)) 
strand_minus<-rep('-',nrow(testSet_minus)) 
strand<-c(strand_plus,strand_minus) 
testSet<-cbind.data.frame(testSetall[,1:3],peak_names[,1],testSetall[,4],strand) 
colnames(testSet)=c('chr','start','stop','name','score','strand') 
peaks <- BED2GRangesSeq(testSet, withSeq=FALSE) 
 
#build feature vectors 
testSet.NaiveBayes <- buildFeatureVector(peaks, BSgenomeName=Hsapiens, 
upstream=40, downstream=30, wordSize=6, alphabet=c("ACGT"), 
sampleType="unknown", replaceNAdistance=30, method="NaiveBayes", 
ZeroBasedIndex=1, fetchSeq=TRUE) 
 
#test against datasets (3PSeq) 
data(data.NaiveBayes) 
predictTestSet(data.NaiveBayes$Negative, data.NaiveBayes$Positive,  
 testSet.NaiveBayes=testSet.NaiveBayes,outputFile= 
 output_filename, assignmentCutoff=0.95) 
  
#find gene names of peaks, remove internally primed peaks 
predicted<-read.table(output_filename, header=TRUE) 
predicted_peaks<-predicted[predicted[,4]>0,] 
rows_left<-predicted_peaks[,1] 
 
#make file of true peaks with gene name and coverage information 
testSet[,4]=peak_names[,2] 
testSet=testSet[rows_left,] 
write.table(testSet, file=bed_peaks, sep='\t', row.names=FALSE, col.names=FALSE, 
quote=FALSE) 
 
#Run bsub -q long -n 24 -W 24:00 -R "rusage[mem=16000]" -o output.log -e error.log 
../ratios_peaks.sh sample_name 
 
#ratios_peaks.sh 
#these programs will normalize the peak read to total reads from the 3′UTR and identify 
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genes with more than one 3′UTR peak. It will also add up all the peaks from the same 
gene to get the total gene coverage. 
 
#!/bin/bash 
#load stuff required 
module load R/3.1.0 
 
Rscript ../all_pA_ratios.R $1_UTRpredictions.bed $1_mpApeaks.bed $1_mpAratios.bed 
Rscript ../all_gene_coverages.R $1_UTRpredictions.bed $1_all_predictions.bed 
$1_combined_peaks.bed $1_combined_coverage.bed 
 
#files for ratios_peaks.sh 
#all_pA_ratios.R 
#takes 4 arguments from command line: 1. input bed file of true peaks in the UTR 
(output from cleanUpdTSeq script) with + and - strand genes 2. output name for file of 
genes/coverage/strand/coordinate information for genes with multiple pA peaks 3. output 
name for file of isoform:total coverage of tandem pA peak genes with gene name, pA 
site, and coverage. 
 
args=commandArgs(T) 
input_UTR_peaks=args[1] 
output_mpA_peaks=args[2] 
output_mpA_ratios=args[3] 
 
all_real_peaks <- read.table(input_UTR_peaks, header=FALSE, 
col.names=c('chr','start','stop','name','coverage','strand'), stringsAsFactors=FALSE) 
 
#remove peaks that map to more than one gene 
p<-all_real_peaks[,1:3] 
q<-p[!(duplicated(p) | duplicated(p, fromLast = TRUE)),] 
all_real_peaks<-all_real_peaks[rownames(q),] 
 
#make first rows to add to in the loop, I will delete these later. mpA_peaks contains info 
for all genes with multiple 3'UTR peaks.  
#Ratio contains name and ratio of isoform: total 3'UTR coverage for each peak from a 
gene with multiple 3'UTR peaks. 
mpA_peaks<-all_real_peaks[1,] 
these_peaks<-all_real_peaks[1,] 
peak_norm<-these_peaks[,5]/sum(these_peaks[,5]) 
ratio<-cbind(these_peaks[,4],peak_norm,these_peaks[,5],these_peaks[,1:3]) 
colnames(ratio)=c('geneID','peak/total','coverage','chr','start','stop') 
indices<-0 
 
for (n in 1:(nrow(all_real_peaks))){ 
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 #only analyze this gene if it hasn’t been analyzed yet 
if (length(which(indices==n))==0){ 
   #find number of 3′UTR peaks that are in this gene 
number_peaks<-
t(as.matrix(which(all_real_peaks[,4]==all_real_peaks[n,4]))) 
   these_peaks<-all_real_peaks[number_peaks,] 
#if the number of peaks is greater than one, add peaks from that gene to 
file of mpA peaks, divide peak coverage by the total reads mapping to the 
gene 3′UTR and add peaks to ratio file 
   if (length(number_peaks)>1) { 
     mpA_peaks=rbind(mpA_peaks,these_peaks) 
     peak_norm<-these_peaks[,5]/sum(these_peaks[,5]) 
     this_gene<-
cbind(these_peaks[,4],peak_norm,these_peaks[,5],these_peaks[,1:3]) 
     colnames(this_gene)<-colnames(ratio) 
     ratio=rbind(ratio,this_gene) 
     rownames(ratio)<-NULL 
     indices=data.frame(indices, number_peaks) 
     } 
  } 
} 
 
#remove the first dummy rows 
mpA_peaks=mpA_peaks[2:nrow(mpA_peaks),] 
colnames(mpA_peaks)=c('chr','start','stop','geneID','coverage','strand') 
 
ratio=as.data.frame(ratio[2:nrow(ratio),]) 
ratio <- as.data.frame(lapply(ratio, unlist)) 
 
#write outputs 
write.table(mpA_peaks, file=output_mpA_peaks, sep='\t', row.names=FALSE, 
col.names=FALSE, quote=FALSE) 
write.table(ratio, file=output_mpA_ratios, sep='\t', row.names=FALSE, 
col.names=FALSE, quote=FALSE) 
 
#all_gene_coverages.R 
#takes 2 arguments from command line: 1. input bed file of true peaks (output from 
cleanupdt seq script) with + and - strand genes 2. output name for file of 
genes/coverage/strand/coordinate/UTRreads combined information. 
#this script will remove duplicate gene names or peak coordinates made by intersectbed 
in all gene file. 
 
#Define inputs and outputs. Output file has name, total reads for gene, strand, and UTR 
reads for gene. 
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args=commandArgs(T) 
input_UTRpeaks=args[1] 
input_allpeaks=args[2] 
output_combined_coverage=args[3] 
 
UTR_peaks <- read.table(input_UTRpeaks, header=FALSE, 
col.names=c('chr','start','stop','geneID','coverage','strand')) 
 
all_peaks <- read.table(input_allpeaks, header=FALSE, 
col.names=c('chr','start','stop','geneID','coverage','strand')) 
 
#remove peaks that fit in more than one gene 
p<-UTR_peaks[,1:3] 
q<-p[!(duplicated(p) | duplicated(p, fromLast = TRUE)),] 
UTR_peaks<-UTR_peaks[rownames(q),] 
 
p<-all_peaks[,1:3] 
q<-p[!(duplicated(p) | duplicated(p, fromLast = TRUE)),] 
all_peaks<-all_peaks[rownames(q),] 
 
#combine all the peaks from one gene 
indices<-0 
combined_peaks<-data.frame(matrix(nrow=nrow(all_peaks),ncol=4)) 
for (j in 1:nrow(all_peaks)) { 
 #only analyze this gene if it hasn’t been analyzed before 
if (length(which(indices==j))==0){ 
  #Continue summing reads until they are no longer in the same gene. 
sum=all_peaks[j,5] 
  if (j<nrow(all_peaks)){ 
   start<-j+1 
   end<-nrow(all_peaks) 
   for (m in start:end){ 
    if (all_peaks[j,4]!=all_peaks[m,4]) { 
     break 
    } 
    else { 
     indices=data.frame(indices,j) 
     indices=data.frame(indices,m) 
     sum=sum+all_peaks[m,5] 
    } 
   } 
  } 
  #Add all the UTR reads that map to the gene 
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  UTR_reads<-which(UTR_peaks[,4]==as.character(all_peaks[j,4])) 
  if (length(UTR_reads)>0) { 
   reads<-sum(UTR_peaks[UTR_reads,5]) 
  } 
  else { 
   reads<-0 
  } 
   combined_peaks[j,1]=toString(all_peaks[j,4]) 
   combined_peaks[j,2]=sum 
   combined_peaks[j,3]=toString(all_peaks[j,6]) 
   combined_peaks[j,4]=reads   
 } 
} 
 
combined_peaks=na.omit(combined_peaks) 
 
 
#write outputs 
write.table(combined_peaks, file=output_combined_coverage, sep='\t', 
row.names=FALSE, col.names=FALSE, quote=FALSE) 
 
#once you have done all of the above on all samples and moved all *mpAratios* and 
*_combined_peaks* to their own folder: 
#Run bsub -q long -n 24 -W 18:00 -R "rusage[mem=16000]" -o output.log -e error.log 
../combine_samples.sh tissue_name  
 
#combine_samples.sh 
#this program combines the gene peak info (isoform ratios or total coverage) for all 
samples. 
#!/bin/bash 
#input is the tissue name for all of the samples (ie cortex) 
 
#load stuff required 
module load R/3.1.0 
 
Rscript ../combine_samples_newest.R $1_all_ratios.tsv $1_all_gene_coverage.tsv 
$1_fracUTRgenecoverage.tsv 
 
#files for combine_samples.sh 
#combine_samples_newest.R 
 
#define outputs, which include the output ratios filename and the output coverage 
filename. 
args=commandArgs(T) 
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output_ratios=args[1] 
output_gene_coverage=args[2] 
output_fracUTR=args[3] 
 
#import relevant files in the working directory 
filenames_ratios<-list.files(getwd(),pattern='*mpAratios*') 
filenames_gene_coverage<-list.files(getwd(),pattern='*combined_peaks*') 
 
just_name_filenames<-substr(filenames_ratios,1,8) 
list_of_ratios<-lapply(filenames_ratios, read.table) 
list_of_gene_cov<-lapply(filenames_gene_coverage, read.table) 
 
names(list_of_ratios) <- filenames_ratios 
names(list_of_gene_cov) <- filenames_gene_coverage 
 
 
#make a list of all unique isoforms represented in the sample datasets for isoform 
coverage 
UTR_iso_names<-cbind(list_of_ratios[[1]][,1],list_of_ratios[[1]][,5:6]) 
colnames(UTR_iso_names)<-c('gene','start','stop') 
for (s in 2:length(list_of_ratios)){ 
  aname<-cbind(list_of_ratios[[s]][,1],list_of_ratios[[s]][,5:6]) 
  colnames(aname)<-c('gene','start','stop') 
  UTR_iso_names=rbind(UTR_iso_names,aname) 
} 
UTR_iso_names=unique(UTR_iso_names) 
 
#make a list of all unique genes represented in the sample datasets for total coverage 
gene_names<-as.matrix(list_of_gene_cov[[1]][,1]) 
for (k in 2:length(list_of_gene_cov)){ 
 gene_names=rbind(gene_names,as.matrix(list_of_gene_cov[[k]][,1])) 
} 
gene_names=unique(gene_names) 
 
#make an output dataframe with the first column for gene name and the other columns 
for isoform ratios or gene coverage for that isoform/gene in each sample 
all_samples_ratios<-
as.data.frame(matrix(ncol=(length(list_of_ratios)+3),nrow=nrow(UTR_iso_names))) 
all_samples_gene_coverage<-as.data.frame(matrix(ncol=(length(list_of_gene_cov)+1), 
nrow=nrow(gene_names))) 
all_samples_fracUTR<-as.data.frame(matrix(ncol=(length(list_of_gene_cov)+1), 
nrow=nrow(gene_names))) 
 
colnames(all_samples_ratios)=c('geneID','start','stop',just_name_filenames) 
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colnames(all_samples_gene_coverage)=c('geneID',just_name_filenames) 
colnames(all_samples_fracUTR)=c('geneID',just_name_filenames) 
 
#fill the dataframe with the ratio/coverage values of the sample if they cover that isoform, 
if not with an NA 
index=0 
for (n in 1:nrow(UTR_iso_names)){ 
 
 all_samples_ratios[n,1:3]=t(as.matrix(c(toString(UTR_iso_names[n,1]),UTR_iso
_names[n,2:3]))) 
  for (j in 1:length(list_of_ratios)){ 
     index=which(list_of_ratios[[j]][,1]==toString(UTR_iso_names[n,1]) &  
          list_of_ratios[[j]][,5]==UTR_iso_names[n,2] &  
          list_of_ratios[[j]][,6]==UTR_iso_names[n,3]) 
     if (length(index)>0){ 
      all_samples_ratios[n,j+3]=list_of_ratios[[j]][index,2] 
     } 
    else { 
      all_samples_ratios[n,j+3]=NA 
    } 
  } 
} 
 
 
#do the same for all gene coverage 
index=0 
for (n in 1:nrow(gene_names)){ 
  all_samples_gene_coverage[n,1]=toString(gene_names[n,1]) 
  for (j in 1:length(list_of_gene_cov)){ 
    index=which(list_of_gene_cov[[j]][,1]==gene_names[n,1]) 
    if (length(index)==1){ 
      all_samples_gene_coverage[n,j+1]=list_of_gene_cov[[j]][index,2] 
    } 
    else { 
      all_samples_gene_coverage[n,j+1]=NA 
    } 
  } 
} 
 
#make a matrix of fraction of total reads corresponding to the 3′UTR for each sample 
index=0 
for (n in 1:nrow(gene_names)){ 
  all_samples_fracUTR[n,1]=toString(gene_names[n,1]) 
  for (j in 1:length(list_of_gene_cov)){ 
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    index=which(list_of_gene_cov[[j]][,1]==gene_names[n,1]) 
    if (length(index)==1){ 
      fraction<-
list_of_gene_cov[[j]][index,4]/list_of_gene_cov[[j]][index,2] 
      all_samples_fracUTR[n,j+1]=fraction 
     } 
     else { 
      all_samples_fracUTR[n,j+1]=NA 
    } 
  } 
} 
 
#write output 
#all_samples_ratios= all mpA peak ratios (iso:totalUTRisos) 
#all_samples_gene_coverage= total coverage of entire gene for all genes 
#all_samples_fracUTR= UTRreads/totalreads for each gene 
 
write.table(all_samples_ratios, file=output_ratios, sep='\t', row.names=FALSE, 
col.names=TRUE, quote=FALSE) 
write.table(all_samples_gene_coverage, file=output_gene_coverage, sep='\t', 
row.names=FALSE, col.names=TRUE, quote=FALSE) 
write.table(all_samples_fracUTR, file=output_fracUTR, sep='\t', row.names=FALSE, 
col.names=TRUE, quote=FALSE) 
 
#then, download the combined samples files, and in local R combine close UTR peaks 
(<40NT apart) created by differences in peak calling amongst samples, shown here for 
MCxGr1 samples: 
 
#input coverage and ratios files 
all_ratios<-read.table('HumMCxGr1_all_ratios.tsv',header=TRUE,fill=TRUE, 
stringsAsFactors=FALSE) 
number_mpA_genes<-nrow(as.matrix(unique(all_ratios[,1]))) 
number_non_mpA_genes<-number_genes-number_mpA_genes 
 
#combine any peaks that are within 40 nucleotides 
ordered <- all_ratios[order(all_ratios$geneID, all_ratios$start),] 
rownames(ordered)<-seq(1,nrow(ordered)) 
#make a first row for the dataframe that I’ll delete later 
this_peak<-ordered[1,] 
indices<-0 
for (k in 1:nrow(ordered)) { 
 #only analyze this row if it hasn’t been analyzed before 
 if (length(which(indices==k))==0) { 
   this_gene<-ordered[which(ordered[,1]==ordered[k,1]),] 
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   rownums<-seq(1,nrow(this_gene)) 
   #only analyze if there is more than one row corresponding to this isoform 
if (nrow(this_gene)>1) { 
     #add this gene to the indices so I can skip the rest of the rows 
indices<-c(indices, rownames(this_gene)) 
     sums=this_gene[2,2]-this_gene[1,2] 
     #find the distance between the coordinates for isoforms from this 
gene 
if (nrow(this_gene)>2) { 
       for (j in 2:(nrow(this_gene)-1)) { 
         sum=this_gene[j+1,2]-this_gene[j,2] 
         sums=rbind(sums, sum) 
       } 
     } 
   #make a matrix of coordinates that are within 40 nucleotides of 
each other 
     close<-as.matrix(which(sums<40)) 
     close_indices<-c(close,close+1) 
     all<-c(rownums,close_indices) 
 #make a matrix of coordinates that are not within 40 nucleotides 
of any other peak, add to output. Close=matrix of indices of rows 
that are within 40 nucleotides of the next row 
not_close<-which(!(all %in% all[duplicated(all)])) 
     for (l in 1:length(not_close)) { 
       this_peak<-rbind(this_peak, this_gene[not_close[l],]) 
      } 
     #do the following if there are more than two peaks within 40 
nucleotides for the gene  
if (nrow(close)>1) { 
        ind=0 
       #combine peaks within 40 nucleotides of each other 
for (r in 1:nrow(close)) { 
         #only do this if this row hasn’t been analyzed 
if (length(which(ind==r))==0) { 
          p=r 
          rows<-vector(mode="numeric", length=0) 
      #ID all rows within 40 nucleotides of this 
row 
           while ((p<nrow(close) && close[p+1]-
close[p]==1) || (p>1 && p<=nrow(close) && close[p]-close[p-1]==1)) { 
             rows=c(rows, close[p],close[p]+1) 
             ind=c(ind,p) 
              p=p+1 
           } 
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           #combine all close peaks into one row, keep 
coordinates of 1
st
 
if (length(rows)>0) { 
             data<-this_gene[unique(rows),] 
             first<-data[1,] 
             for (j in 1:(nrow(data)-1)) { 
               real<-
which(!is.na(data[j+1,4:ncol(data)])) 
               first[1,(real+3)]<-
data[j+1,(real+3)] 
              } 
             #add to output 
this_peak<-rbind(this_peak, first) 
           } 
           else { 
             data<-
this_gene[close[r]:(close[r]+1),] 
             first<-data[1,] 
             real<-
which(!is.na(data[2,4:ncol(data)])) 
             first[1,(real+3)]<-data[2,(real+3)] 
             this_peak<-rbind(this_peak, first) 
           } 
         } 
       } 
     } 
     #do the following if there are only two peaks within 40 nucleotides 
of each other 
else if(nrow(close)==1) { 
      real<-which(!is.na(this_gene[(close+1),4:ncol(this_gene)])) 
      this<-this_gene[close,] 
      this[1,(real+3)]<-this_gene[(close+1),(real+3)] 
      this_peak<-rbind(this_peak, this) 
    } 
} 
   #if there is only one row corresponding to this gene, just add it to the 
output. 
else { 
     this_peak=rbind(this_peak, ordered[k,]) 
   } 
} 
}   
 
this_peak<-this_peak[2:nrow(this_peak),] 
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this_peak<-this_peak[order(this_peak$geneID, this_peak$start),] 
all_ratios<-this_peak 
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